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Abstract of the Dissertation
Mitochondria exist in a highly dynamic network in many cell types, and mutations in
mitochondrial transmembrane GTPase mitofusin2 (MFN2), a key factor that mediates
mitochondrial tethering, cause defects in the nervous system. Intriguingly, the skeleton has been
overlooked in patients with such mutations. Because expression of MFN2 and its homolog,
mitofusin1 (MFN1) increase with maturation of osteoclasts (OCs), which are rich in
mitochondria, we sought to determine the role of mitofusins in the OC lineage. Double knockout
of Mfn1 and Mfn2 in OC precursors by Lysozyme-M cre reveals that mitofusin activity is
required for OC function and maintenance of bone mass in female mice in vivo. In vitro, double
knockout bone marrow macrophages are unable to differentiate into mature OCs. Here, OC
formation in dcKO BMMs is restored when Mfn2 but not Mfn1 is retrovirally overexpressed. To
further explore the role of MFN2 in the OC lineage, we conditionally deleted Mfn2 with LysMcre and find bone mass is increased in aged female Mfn2 cKOs compared to cre-only littermates.
Challenging these single MFN2 knock out animals with acute RANKL injection indicates that
Mfn2 is important in female, but not male, OCs, because female Mfn2 cKOs are protected from
bone loss with this osteolytic stimuli. Specific MFN2 functions were further assessed in culture.
While a MFN2 mutant defective in mitophagy is able to promote osteoclastogenesis, another
unable to tether mitochondria is not. This suggests that tethering of mitochondria to eachother
and/or the ER by MFN2 is required for osteoclast differentiation, at least in culture. Taken
together, our results reveal a sexually divergent role of MFN2-mediated control of mitochondrial
dynamics in OC biology. Given the differences in female mice, there may be therapeutic
potential to target MFN2 activity for treatment of postmenopausal osteoporosis.
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Chapter 1 – Introduction
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Part 1 – Osteoclasts
Skeletal homeostasis
The skeleton is an organ constantly remodeling and responding to interactions with other
bodily systems and external factors. Bone homeostasis relies on the coupled activity of
osteoblast (OB) and osteoclast (OC) cells that build and resorb the bone matrix, respectively.
During development, organic matrix is deposited and subsequently mineralized by OBs to form
hydroxyapatite from calcium and phosphate. The OC destroys both the organic and inorganic
components of the bone matrix through release of acids and proteases at sites of bone
remodeling. When skeletal integrity is properly maintained, these two cell types constantly
remodel bone at a rate of complete bone turnover every 10 years (reviewed in (Novack, 2011).
The bone environment includes chondrocytes that reside on joint surfaces and maintain
articular cartilage. Osteocytes are imbedded in the bone matrix and are OB-derived, functioning
to relay signals from mechanical stimuli. In response to mechanical demands and fracture
healing, bone formation is favored. Without these stimuli, bone mass decreases in conditions of
unloading. OC formation and function are regulated by a number of factors in the body, and
hormonal or inflammatory stimulation of OC activity that is not matched by OBs can lead to
pathogenic decreases in bone mass (reviewed in (Novack, 2011; Ono, 2018)). Under
homeostatic conditions, bone remodeling is coupled, whereby products released by OC-mediated
matrix degradation recruit OBs, and OBs in turn secrete factors that induce OC differentiation
(Henriksen et al., 2013; Martin and Sims, 2005; Novack and Teitelbaum, 2008).
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Cellular morphology/components
The unique morphology of the mature OC allows it to efficiently resorb the bone. These
multinuclear cells become polarized when in contact with the bone surface creating an area,
termed the resorption lacuna, where the section of bone to be excavated is isolated. At this
junction, called the ruffled border, numerous expansions of the membrane allow large surface
areas for transport of cargo into the lacuna by trafficking down microtubules and microfilaments,
which is controlled by small GTPases (reviewed in (Cappariello et al., 2014; Novack and Faccio,
2011)).
Inorganic and organic components make up the bone matrix. Inorganic crystalline
hydroxyapatite mineral, [(Ca3(PO4)2]3Ca(OH)2, must be dissolved acidically. This is achieved
by the transport of protons to the resorption lacuna by the vacuolar H+-ATPase on the ruffled
border that creates a pH of ~4.5 and liberates calcium from hydroxyapatite (Gay and Mueller,
1974; Silver et al., 1988). Because H2CO2 is utilized as a proton source, it dissociates into H+
which is pumped into the lacuna, and the remaining bicarbonate is removed from the OC
cytoplasm via a chloride-bicarbonate exchanger on the basolateral membrane. This also brings
Cl- into the cell which is also delivered to the resorption lacuna by Cl- channels charge coupled
to the H+-ATPase (Blair et al., 1991). Proteolytic enzymes, primarily cathepsin K (CatK), are
active at low pH and degrade type I collagen and other organic components of the bone matrix
(Bossard et al., 1996; Drake et al., 1996).
The membrane at the sealing zone is anchored to the bone surface via integrin-mediated
adhesion, primarily by integrin αvβ3. In close proximity to integrin αvβ3 is a belt of podosomes
that form a ring around the periphery of the resorption lacuna (Destaing et al., 2003). Comprised
of F-actin and microtubules, these structures are highly dynamic and isolate only areas being
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actively resorbed (SALTEL et al., 2008). Here, when OCs migrate, cytoskeletal remodeling
includes disassembly of sealing zones and lamellipodial movement, then subsequent attachment
to a new location with integrin αvβ3 adherence and nascent podosome formation (reviewed in
(Novack and Faccio, 2011; Teitelbaum, 2011)) (Fig. 1.1).

Figure 1.1: Bone remodeling
A). Under homeostatic conditions OB build the bone resorbed by OCs at an equal rate to
maintain bone mass. B). Cellular components that allow for proper acidification of the
resorption lacuna, adapted from (Novack and Teitelbaum, 2008).
Differentiation/activation signaling
OCs are derived from hematopoietic stem cells in the bone marrow by way of cKit+CD11bloc-Fms+ common myeloid progenitors (Arai et al., 1999). Cells from this
macrophage/monocyte lineage become committed to an OC fate when exposed to two cytokines,
macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand
(RANKL). Both factors are required for OC formation, and are sufficient to form OCs from
bone marrow macrophage precursors in vitro (Quinn et al., 1998). While M-CSF works through
tyrosine kinase receptor c-Fms to promote survival and proliferation of OC lineage cells,
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RANKL interacts with the RANK receptor to initiate differentiation through alternative NF-κB
signaling (Novack and Teitelbaum, 2008). RANKL (encoded by Tnfsf11), a transmembrane
protein member of the TNFR superfamily that harbors several TRAF-binding domains, is
produced most highly by osteoblasts and osteocytes (Nakashima et al., 2011; Nelson et al.,
2012). Although osteoclastogenesis is aided by co-stimulatory action of ITAM signaling that
with RANKL modulates calcineurin, MAPK, PI3K and Src signaling, NF-κB remains
indispensable for OC formation (Novack, 2011). When NF-κB is activated by membrane-bound
or soluble RANKL interacting with the RANK receptor on OC precursors, RANK binds TNF
receptor-associated factor 3 (TRAF3), which stabilizes NF-κB inducing kinase (NIK). Because
NIK is ubiquitinated and degraded in the absence of RANKL activation, its stabilization allows
NIK to phosphorylate and activate IκB kinase alpha (IKKα). Consequently, IKKα activation
leads to p100 and RelB processing in the proteasome so that p52 (resulting from partial
degradation of p100) and RelB can translocate to the nucleus. Of most importance, this results in
the activation of two transcription factors required for osteoclastogenesis, c-Fos, and NFATc1
(reviewed in (Novack, 2011; Ono, 2018)).
NFATc1 is a master regulator of osteoclastogenesis, and with its induction and autoamplification, transcription of multiple osteoclast-specific genes are induced (Ishida et al., 2002;
Takayanagi et al., 2002). To name a few, cathepsin K is important for bone resorption as
described above, tartrate resistant acid phosphatase (TRAP) is a potent OC marker, and DCSTAMP mediates OC fusion (BURSTONE, 1959; Yagi et al., 2005). Interestingly, NFATc1 is
highly susceptible to Ca2+ fluxes and requires dephosphorylation by calcineurin for translocation
to the nucleus (Hogan et al., 2003). Here, many groups have demonstrated that heightened Ca2+
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oscillations in the cytoplasm following RANKL stimulation are associated with increased
osteoclastogenesis (Kim et al., 2013; Takayanagi et al., 2002; Yang et al., 2009).
Bioenergetics in the OC
Compared to other cells, OCs have the ability to function in low oxygen conditions
between 1.5-6.3% pO2 (atmospheric O2 = 21% and majority of tissues operate between 5-12%)
(Spencer et al., 2014). Hypoxia actually increases osteoclastogenesis in vitro (Arnett et al.,
2003). With their ability to function in a variety of cellular conditions, OCs may use fatty acids
and glucose to support both aerobic and anaerobic respiration during osteoclastogenesis
(reviewed in (Arnett and Orriss, 2018)). Further, metabolic byproducts of H+ ions and reactive
oxygen species have beneficial effects on OCs by stimulating OC activity and aiding
acidification of the resorption lacuna (Arnett and Dempster, 1986; Callaway and Jiang, 2015).
OCs are rich in mitochondria and differentiation from bone marrow macrophage
precursors to OCs is associated with significant increase in mitochondria copy number, oxidative
phosphorylation (OxPhos) subunits, and oxygen consumption (Zeng et al., 2015). Alternative
NF-κB signaling that is crucial for osteoclastogenesis also regulates mitochondrial biogenesis
and function in skeletal muscle, and modulates the expression of mitochondrial biogenesis factor,
PPARγ cofactor 1β (PGC-1β), in the OC (Bakkar et al., 2012; Zeng et al., 2015). Loss of PCG1β in the OC results in impaired cytoskeletal organization and bone resorption in addition to
decreased mitochondrial biogenesis (Zhang et al., 2018).
OCs require vast amounts of energy to resorb bone, and these cells utilize glucose and
glutamine as primary sources for respiration (Indo et al., 2013). As OCs operate in the hypoxic
environment of the bone, resorption becomes an energy-intensive operation. Upon
differentiation from bone marrow macrophage precursors, pre-OCs exposed to RANKL undergo
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a metabolic shift toward accelerated glycolytic and oxidative metabolism, ultimately leading to
increased ATP production and electron transport chain activity (Kim et al., 2007; Morten et al.,
2013). Accordingly, metabolic enzymes are upregulated during osteoclastogenesis and oxygen
consumption rates increase compared to macrophages in mouse-derived cells (Czupalla et al.,
2005; Zeng et al., 2015).

Additional functions of the OC
In addition to bone resorption, studies have also shown OCs to have roles in regulating
hematopoiesis, bone formation, intraosseous angiogenesis, and osteocalcin hormonal functions.
Cathepsin K and matrix metalloproteinase MMP9 produced by the OCs mobilize CXCL12 and
c-Kit that regulate hematopoietic stem cells (HSCs), and treatments targeting the OCs such as
strontium, prostaglandin, and bisphosphonates, have additional effects on HSCs (Frisch et al.,
2009; Lymperi et al., 2011; 2008). During resorption OCs release products from the bone matrix
that induce bone formation. These are termed “clastokines” and are anabolic agents that recruit
OB precursors to the bone matrix such as TGFβ, bone morphogenetic proteins, fibroblast growth
factors, and insulin-like growth factor (reviewed in (Cappariello et al., 2014; Teti, 2013). Other
factors such as VEGF-A and HIF1α induce angiogenesis (Chim et al., 2013; Trebec-Reynolds et
al., 2010).

Mouse models and cres
Cre-Lox technology allows researchers to selectively delete genes of interest in specific
tissues through mating genetically engineered animals harboring a floxed gene and cre
recombinase expressed by tissue-specific transcription factors (Yarmolinsky and Hoess, 2015).
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The study of factors important in OC formation and function has been aided by the development
of multiple cre drivers in the OC lineage. Early deletion of floxed alleles can be achieved with
use of Lysozyme M-cre, CD11b-cre, and RANK-cre, while genes may be conditionally deleted
in mature OCs via Cathepsin K-cre (reviewed in (Elefteriou and Yang, 2011)).
While mice display highest levels of bone mass at 4 months of age, OCs generally have
greatest activity at 2 months, as evidenced by serum CTX, a marker for bone resorption, reaching
peak elevation in B6 mice (Amend et al., 2015). Common experimental techniques to induce
OC differentiation and activity include exposing mice to RANKL injected subcutaneously or
intraperitoneally (Shashkova et al., 2016). Induction of inflammatory arthritis has also been
shown to induce OC activity (Decker et al., 2015; Seeling et al., 2013). Such induction of
pathological bone loss can produce robust OC phenotypes, and uncover phenotypes not apparent
under basal physiological conditions (Novack et al., 2003; Vaira et al., 2008). This is also seen
in models of ovariectomy (OVX), a model of postmenopausal osteoporosis that induces OC
activity through estrogen deficiency (Anginot et al., 2007; Wu et al., 2007).
Mouse models have been immensely useful in elucidating the impact of signaling
components of the osteoclast and overall bone health. For example, ablation of NF-κB
components, RANK, RANKL, Cathepsin K, αvβ3 integrin, NFATc1, in murine models all lead
to high bone mass osteopetrotic phenotypes (reviewed in (Novack and Teitelbaum, 2008; Xu and
Teitelbaum, 2013)).
In contrast to osteoporosis, osteopetrosis is a genetic condition in which bone mass and
density are increased because of a failure of bone resorption by OCs. Most often, humans
present with forms of either OC-poor or OC-rich osteopetrosis whereby the disease manifests
due to a failure of OCs to differentiate or function, respectively. Either form of the disease is
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often accompanied by hematological impairment and decreased life expectancy (reviewed in
(Sobacchi et al., 2013)). As mouse models closely phenocopy human ailments, it is critical that
mouse models of OC dysfunction be studied closely.
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Part 2 – Mitochondrial dynamics
Mitochondrial networks
Mitochondria exist within a dynamic network in most cell types and are highly regulated.
Here, termed mitochondrial dynamics, the processes of tethering/fusion, fission, and mitophagy
play an important role in mitochondrial homeostasis. Changes in mitochondrial networks are
frequent, and this architecture is varied depending on the developmental or metabolic needs of a
cell (reviewed in (Dorn et al., 2015; Schrepfer and Scorrano, 2016; Ventura-Clapier et al.,
2008)).
As the organelles become more connected with increased fusion, ATP production
increases because networks allow exchange of mtDNA and metabolites between once-separated
mitochondria. In particular, fusion of mitochondria under stressful conditions prevents
autophagy and allows ATP production to be optimized due to increased cristae density favoring
ATPase oligomerization (Gomes et al., 2011; Rambold et al., 2011). Fusion is accomplished
through coordinated rearrangement of both the outer and inner mitochondrial membranes (OMM
and IMM, respectively), which are mediated by MFN1/MFN2, and OPA1, respectively.
Mammalian mitofusins MFN1 and MFN2 are ~80% homologous, each consisting of an Nterminal cytosolic GTPase domain, a coiled coil heptad-repeat (HR1) domain, two
transmembrane domains, and heptad-repeat domain (HR2) at the C-terminus (reviewed in (Filadi
et al., 2018b)).
Accumulation of mitofusins in regions of contact in neighboring mitochondria precedes
fusion events (Mozdy and Shaw, 2003). It is generally accepted that fusion is achieved first
through antiparallel binding of the carboxy-terminal α-helical HR domains of MFN1 and/or
MFN2. This brings GTPase heads together for subsequent GTP hydrolysis and dimerization
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(reviewed in (Dorn, 2019; Koshiba et al., 2004). Intriguingly, MFN2 exhibits two alternative
conformations that make its state tethering-permissive or tethering-non-permissive. Only
tethering-permissive intramolecular interactions of MFN2 allow the HR2 domain exposure into
the cytosol to tether with the HR2 of an adjacent mitofusin protein (Franco et al., 2016). When
tethering is successful, GTP hydrolysis then induces OMM fusion of the two mitochondria
(Koshiba et al., 2004; Lee and Yoon, 2016). Following OMM fusion, OPA1 anchored on one
IMM binds to cardiolipin on another IMM, whereby subsequent tethering and GTP hydrolysis by
OPA1 fuses the two membranes (Ban et al., 2017; Lee and Yoon, 2018).
Conversely, networks become fragmented to prevent nutrient overload. In this state,
oxidative stress and mitochondrial depolarization increase, and ATP production is blunted with
an increase in mitochondrial uncoupling and nutrient storage (Jheng et al., 2012; Molina et al.,
2009). Mitochondrial fission requires recruitment and post-translational modifications of DRP1,
a cytosolic GTPase dynamin 1-like protein, to the OMM, where it promotes fission with
interaction of fission proteins, MFF, MID51, MID49, and FIS1 (reviewed in (Hu et al., 2017)).
Additionally, mitochondrial dynamics allow for strict quality control of organelles, as
damaged mitochondria can be sequestered from the network and degraded via a specialized form
of autophagy referred to as mitophagy (reviewed in (Ashrafi and Schwarz, 2013; Shirihai et al.,
2015). Here, it is generally accepted that PINK1 kinase responds to mitochondrial
depolarization, ROS production, and protein misfolding to induce mitophagy ((Jin and Youle,
2013; Matsuda et al., 2010; Narendra et al., 2010)). PINK1 phosphorylates MFN2 on three
residues to promote removal of damaged mitochondria. Ser378 phosphorylation induces the
tethering-non-permissive state, prohibiting mitochondrial fusion (Rocha et al., 2018).
Phsosphorylation on Thr111 and Ser442 recruits E3 ubiquitin ligase PARKIN to bind MFN2
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(Chen and Dorn, 2013). With mutation of these threonine and serine residues to glutamic acid or
alanine, mitophagy signaling is either constitutively activated or repressed, respectively (Gong et
al., 2015). When recruited by MFN2, PARKIN subsequently mediates mitochondrial targeting
to the autophagosome (reviewed in (Dorn et al., 2015; Gustafsson and Dorn, 2019)).
Independent of PINK1/PARKIN signaling, mitochondria can also be cleared by direct
engulfment into the lysosome or through clearance by the endosomal sorting complexes required
for transport (ESCRT) machinery that ultimately delivers mitochondria to the lysosome
(reviewed in (Moyzis and Gustafsson, 2019).

Figure 1.2: Depiction of mitochondrial dynamics and key players
Mitochondrial dynamics includes the fission, fusion, and mitophagy of mitochondria. Of note,
MFN1 and MFN2 participate in the tethering/fusion of one mitochondria to another, and
tethering of mitochondria to the ER by MFN2 impacts Ca2+ signaling. Adapted from (Gao et al.,
2014).
12

Mitofusins
As introduced above, transmembrane GTPases MFN1 and MFN2 are key players in
mitochondrial dynamics. Both are necessary for survival, as deletion of either mitofusin is
embryonic lethal, at mid-gestation in murine models. The majority of Mfn1 or Mfn2 knock out
(KO) embryos are resorbed prior to E12.5, and in the case of Mfn2 KO, placenta formation is
impaired. Double deletion of Mfn1 and Mfn2 leads to even earlier mortality (Chen et al., 2003).
Morphologically in MEFs, knockout of Mfn1 or Mfn2 leads to severely fragmented
mitochondrial networks (Chen et al., 2003). Decreased oxygen consumption is also a feature of
cells lacking Mfn1 and Mfn2 in murine cell cultures (Chen et al., 2005; Song et al., 2015).
To combat the lethality associated with global mitofusin knockout, floxed alleles have
been generated to study Mfn1 and/or Mfn2 loss conditionally. Similarly to whole body single
and double KO of Mfn1 and/or Mfn2, systems such as cardiac muscle display more robust
defects in morphology and function when both Mfn1 and Mfn2 are deleted compared to deletion
of either homolog alone (Chen et al., 2010; Papanicolaou et al., 2012a; Song et al., 2015).
Changes in mitofusin expression can be observed as the connectivity of mitochondria
decreases. This generates mitochondrial aspect ratios that can be compared, as higher ratios
indicate a greater degree of fused/networked organelles (Gong et al., 2015). While MFN1 solely
participates in mitochondrial tethering/fusion, MFN2 mediates mitophagy as well as assists in
mitochondrial transport and serves as a mitochondrial tether to the ER (Figure 1.2). Transport of
mitochondria down axons also requires functional MFN2 whereby MFN2 interacts with MIRO
and MILTON motor proteins that allow mitochondrial attachment to microtubules (Misko et al.,
2010). Branching and enervation of nerve fibers to dopamine neurons is also compromised in
dopamine neuron specific Mfn2 cKO (Lee et al., 2012).
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The connection between mitochondria and the ER is important for regulation of many
cellular functions including Ca2+ signaling, lipid biosynthesis, apoptosis, and the ER stress
response (reviewed in (Filadi et al., 2018a; van Vliet and Agostinis, 2018)). Studies using Mfn2
knockdown cells have revealed that ablation of Mfn2 increases mitochondria distance to the ER,
and loss of the protein leads to impaired Ca2+ calcium uptake in the mitochondria (de Brito and
Scorrano, 2008; Filadi et al., 2016; Naon et al., 2016). Buffering of Ca2+ by the mitochondria
functions to maintain cellular functions including metabolism and survival, further implicating
the importance of Mfn2. Accordingly, mouse heart and hematopoietic stem cell models lacking
Mfn2 sustain defects in calcineurin signaling including aberrant induction of downstream
transcription factors NOTCH1 and NFAT, respectively (Kasahara et al., 2013; Luchsinger et al.,
2016). Recently, structural insights into MFN2 GTPase and HR domains have allowed groups to
probe the specific function of particular residues in vitro. For example, MFN2 K416R mutation
disallows ubiquitination by Parkin that required for the physical interaction between
mitochondria and ER, as K414R increases distance between organelles and reduces
mitochondrial Ca2+ uptake in MEFs (Basso et al., 2018). Another mutant, MFN2 F223L,
represses mitochondrial fusion, but does not alter mitochondrial proximity to one another by
tethering assay. Tethering to the ER was not assessed in this model (Engelhart and Hoppins,
2019).

Mfn2 disease importance
The nervous system is highly impacted by Mfn2 defects, and Mfn2 mutations are linked
to disorders of the central and peripheral nervous system that lead to neuropathies and sensory
loss (reviewed in (Celsi et al., 2009; Filadi et al., 2018b)). One of the leading neuropathies
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associated with mutations in Mfn2 is Charcot-Marie-Tooth type 2A syndrome (CMT2A), a
neurodegenerative disease in which motor and sensory defects develop within the first two
decades of life. Over 100 dominant Mfn2 mutations are linked to CMT2A, and are responsible
for nearly 100% of cases. In the clinic, these patients generally present with sensory loss in the
feet, lack of tendon reflexes, and postural tremors (Adam et al., 1993; Züchner et al., 2004). On
a molecular level, axonal degeneration is observed and mitochondrial transport along
microtubules is impaired with CMT2A, and often, mitochondria are reported accumulating
abnormally in distal sites of axons, making the longest axons most severely affected (Cartoni et
al., 2010; Funalot et al., 2009; Misko et al., 2010).
Mitochondrial fusion defects are observed in CMT2A as well (Funalot et al., 2009; Sole
et al., 2009), with the majority of Mfn2 missense mutations arising near or within the coiled-coil
and GTPase regions of the protein important for initial tethering between mitochondria and
completion of fusion, respectively. These defects have been modeled in zebrafish and
drosophila, as well as mice (Sandoval et al., 2014; Vettori et al., 2011). Mouse models
corroborate the phenotypes seen in humans as mice perform poorly in open field tests (Strickland
et al., 2014), and cultured human cells from CMT2A patients have decreased electrical properties
and reduced mitochondrial membrane potential (Loiseau et al., 2007; Saporta et al., 2015).
Apart from the nervous system, decreased mitofusin expression is associated with
Alzheimer’s Disease, poor prognosis in breast cancer, and insulin resistance in diabetes (Bach et
al., 2003; Manczak et al., 2011; Wang et al., 2009; Xu et al., 2017). Parkinson’s Disease has
also been linked to PINK1/PARKIN mutations (Lee et al., 2012). Intriguingly, two families with
Charcot-Marie-Tooth Syndrome have been reported to also suffer from dilated cardiomyopathy
(Sevillano Fernández et al., 1994; Yoshida et al., 1991). Apart from these cases, defects in
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mitochondrial dynamics have not been specifically linked to irregularities in human hearts
(Dorn, 2016). However, model organism and human cell culture models lacking mitofusins
yield conditions of myocardial hypertrophy, heart tube contractile dysfunction, and vascular
smooth muscle cell proliferation, to name a few (Dorn, 2016; Eschenbacher et al., 2012; Guo et
al., 2007).
Studies in cardiomyocytes have revealed an important role for MFN2 function during
development whereby mitophagy is a requisite for metabolic reprogramming of mammalian
hearts as glycolytic mitochondria are replaced with ones optimized for fatty acid metabolism
(Gong et al., 2015). Here, post-natal conditional knock out of Mfn2 in cardiomyocytes begets
cardiomyopathy with accumulated dysfunctional mitochondria, and in adults, Mfn2 cKO in
cardiomyocytes manifests with enlarged hearts and dilated cardiomyopathy (Papanicolaou et al.,
2011; 2012a). Furthermore, defects in MFN2 or PINK1/PARKIN machinery can lead to
myocardial injury and cardiomyopathy (Billia et al., 2011; Kubli et al., 2013). Accordingly,
selective loss of MFN2 mitophagy function in mice leads to cardiomyopathy and lethality by 8
weeks of age, but pups with fusion-deficient MFN2 are indistinguishable from wild type
littermates (Gong et al., 2015). Of note, human Mfn2 mutations identified through sequencing
databases produce phenotypes such as mitochondrial fragmentation in MEFs and dilation of the
heart tube in Drosophila (Eschenbacher et al., 2012).

16

Part 3 – Study Goals
Rationale for study of mitofusins in the OC
OCs are an incredibly dynamic cell type and during osteoclastogenesis, BMMs go
through many conformational changes including fusion to become mature multinucleated OCs.
Here, we anticipate that mitochondrial networks will be remodeled and ultimately increased
tethering/fusion may be required for completion of this differentiation process. Preliminary
studies in our laboratory using MitoTracker Green FM staining have demonstrated that control
pre-OCs derived from Mfn2+/+; LysMc/c mice have highly networked mitochondria, confirming
what others have has been shown with elongated mitochondria in human OCs by TEM and antimitochondria antibodies (Lemma et al., 2016). In contrast, we find that pre-OCs of Mfn2fl/fl;
LysMc/c mice where Mfn2 is conditionally deleted in the OC lineage lose this degree of
connectivity in mitochondrial networks, suggesting the absence of Mfn2 compromises the ability
of mitochondria in the OC to fuse with one another.
To our knowledge, the consequence of this observation has never been investigated.
Further, bone phenotypes have never been evaluated in humans with Mfn2 mutations such as in
CMT2A, likely because when faced with neurodegenerative ailments, skeletal effects are
presumed to be secondary to the immobility and/or neurological changes patients experience. In
other cell types, the effect of Mfn1 vs. Mfn2 knockout are not always identical, and in particular,
double knock out of Mfn1 and Mfn2 produce more severe phenotypes than single knockout of
either mitofusin alone. We anticipate this could be the case in the OC lineage as well.
Therefore, we have generated mouse models in which Mfn1 and Mfn2 are conditionally deleted
in the OC lineage separately and in combination. In Aims I and II of our study, we explore how
bone mass is affected in these three murine models and expect this will inform how the mitofusin
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proteins support osteoclast formation and/or function. It is possible that the efficiency of OCs to
resorb bone is heightened with highly networked mitochondrial architecture, therefore requiring
mitochondria-to-mitochondria tethering and fusion. Alternatively, Mfn1 and/or Mfn2 could be
necessary for OCs to form, possibly due to altered Ca2+ signaling when tethering of mitochondria
to the ER is altered. We hypothesize that mitochondrial tethering might accompany OC cell
fusion during osteoclastogenesis, and that tethering of mitochondria to each other or the ER is
important for OC formation and/or function.
In addition, considering that in other cell types one function of MFN2 is seemingly
predominant over the other, we hypothesize that tethering/fusion is more important than
mitophagy for OC function. Though autophagy proteins are essential for generating the ruffled
boarder and for bone resorption in OCs (DeSelm et al., 2011), we suspect fusion events for OCs
to become large multinucleated will also require tethering and fusion of mitochondrial networks.
Therefore, in Aim III, we investigate which function is dominant in the OC lineage through
utilizing different Mfn2 mutants that selectively disable tethering or mitophagy. Since MFN2
residues T111 and S442 are phosphorylated in order for mitophagy signaling to proceed,
mutagenesis of both to alanine (designated as Mfn2-AA) ablates PARKIN recruitment to the
mitochondria and prevents mitophagy from occurring. Alternatively, T111E and S442E
mutations (designated Mfn2-EE) promotes spontaneous mitophagy and with the absence of a
fusion signal, mitochondrial networks become fragmented (Gong et al., 2015).
Uncoupling the function of tethering/fusion and mitophagy in the OC lineage will
elucidate the mechanism through which MFN2 modulates OC formation and/or function. Such
knowledge regarding MFN2 action in the OC lineage will inform the novel relationship between
this mitochondrial GTPase and skeletal integrity, a connection that may have the potential to be
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exploited therapeutically for patients suffering from diseases of bone remodeling like
osteoporosis and osteopetrosis.

Specific Aims:
Aim 1 – How is bone mass affected when Mfn2 is deleted from the OC lineage?
Aim 2 – Is there redundancy between MFN1 and MFN2 in the OC lineage?
Aim 3 – Are tethering/fusion and mitophagy functions of MFN2 important in the OC
lineage?
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Chapter 2 –
Loss of mitofusins in the OC lineage inhibits OC formation
and function in murine models and cell culture systems
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Introduction
To investigate the role of mitofusins in the OC, we explore the how loss of Mfn1 and
Mfn2 alone and in combination affect the ability of OCs to form and function in vivo and in
vitro. Specifically, we test whether the activities of MFN1 and MFN2 are redundant and address
which homolog has a greater impact on bone mass and osteoclastogenesis. To our knowledge,
this is the first investigation of these genes in the osteoclast lineage. We use three conditional
mouse models in which Mfn1, Mfn2, or both mitofusins are deleted in the lineage by
LysozymeM-cre. µCT analysis of murine femurs is used as our primary readout of changes in
bone mass in these models. Cell culture experiments are also undertaken to differentiate BMMs
from these mice to OCs in vitro. We find that while deletion of Mfn1 and Mfn2 singularly does
not affect bone mass in young animals, double knockout increases bone mass in female but not
male mice. This corresponds with an inability of OCs to form in culture. Further, as rescue of
osteoclastogenesis occurs with the overexpression of MFN2 but not MFN1 in these double
knockout BMMs, we report that in the OC lineage, Mfn2 plays a dominant role. Accordingly,
stressing Mfn2 cKO mice with age and induced osteolysis reveals MFN2 presence supports OC
activity.
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Materials and methods
Reagents and mice
Double floxed Mfn1fl/fl; Mfn2fl/fl animals were mated to C57Bl/6 mice harboring the
LysM-cre allele, and all mice used for study had two copies of LysM-cre (Chen et al., 2007;
Clausen et al., 1999). To generate dcKOs, double heterozygous (Mfn1fl/+; Mfn2fl/+;LysMc/c) mice
were first bred together and dcKO (Mfn1fl/fl; Mfn2fl/fl; LysMc/c) female progeny mated to double
heterozygous males to generate the cohort of double heterozygous controls and dcKOs. In
parallel, cre-only (Mfn1+/+; Mfn2+/+; LysMc/c) females from the original double heterozygous
mating were bred to double heterozygous males to generate the cohort of cre-only and control
animals. The single Mfn2 cohort was generated using heterozygous breeding pairs so that
progeny genotypes included cre-only (Mfn2+/+; LysMc/c) and cKOs (Mfn2fl/fl; LysMc/c). The same
strategy was employed to generate Mfn1 cre-only and cKO littermates (Mfn1+/+; LysMc/c and
Mfn1fl/fl; LysMc/c, respectively)
Mice were housed communally with ad libitum access to fresh chow and water in a
pathogen-free temperature controlled barrier facility. Daily observation and weekly cage change
was provided by staff of the Division of Comparative Medicine (DCM). Lab members
coordinated animal husbandry and breeding, and the DCM veterinarian assessed all health
concerns. All protocols were approved by Washington University School of Medicine’s Animal
Studies Committee (ASC protocol #20170025).

Micro-computed tomography
Following dissection of right femurs from 2, 4, and 12-month old animals, bones were fixed in
10% neutral buffered formalin (Di Ruscio & Associates, Inc., Fenton, MO) for 24 hours, and
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then stored in 70% ethanol. Ex vivo trabecular and cortical scans were acquired proximal to the
growth plate and at the mid-shaft of the femur, respectively (µCT40, Scanco, Brüttisellen,
Switzerland) (10 µm resolution, 55kVp, 145 µA, 300 seconds integration time). In vivo scanning
of tibias was performed at 21.5 µM resolution (70 kVp, 114 µA, 8W, 100ms integration time) on
VivaCT 40 (Scanco, Brüttisellen, Switzerland). Trabecular bone compartment was analyzed
distal to the end of the tibial growth plate. Thresholds for VivaCT and µCT were determined in a
blinded manner and analyzed with reference to accepted guidelines (Bouxsein et al., 2010;
Nazarian et al., 2008).

CTX1 and P1NP
Serum was collected from animals fasted overnight via mandibular bleed (BD
Microtainer), and stored at -80˚C. RatLaps CTX-1 and P1NP EIA assays was conducted
according to manufacturer’s instructions (Immunodiagnostic Systems, Gaithersburg, MD, USA;
AC-06F1 and AC-33F1, respectively).
Histomorphometry
2 month-old mice were injected intraperitoneally (IP) with 10mg/kg calcein (C0875;
Sigma, USA) and 30 mg/kg alizarin red (A3882; Sigma, USA) seven and two days prior to
sacrifice. Intact femur/tibias were fixed in 10% neutral buffered formalin for 24 hrs prior to
storage in 70% ethanol. Tissues were embedded in methymethacrylate and sectioned sagittally
by the Washington University Musculoskeletal Histology and Morphometry Core. 20X highresolution slide images were acquired using a NanoZoomer 2.0 with brightfield and
FITC/TRITC (Hamamatsu Photonics, Japan). Images were then analyzed via Bioquant Osteo
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software according to manufacture’s instructions and published standards (v18.2.6; Bioquant
Image Analysis Corp., Nashville, TN, USA)(Dempster et al., 2012).

Bone marrow macrophage isolation and osteoclast differentiation
BMMs were harvested by collecting bone marrow from dissected long bones via
centrifugation at 10,000 rpm, passed through a 40µm filter and cultured with α-MEM (Sigma
M0894, St. Louis, MO, USA) containing 10% FBS (Gibco, Grand island, NY, USA), 100 IU/ml
penicillin/streptomycin, and 1:10 dilution of CMG 14-12 cell supernatant (containing equivalent
of 100ng/ml M-CSF) (Novack et al., 2003; Takeshita et al., 2000).
Expanded BMMs were plated at a density of 9,000 and 300,000 cells per well for 96 and
6 well plates, respectively. Purified GST-RANKL at 30ng/ml was added to α-MEM containing
10% FBS, 100 IU/ml penicillin/streptomycin, and 1:50 dilution of CMG 14-12 cell supernatant.
Media was changed every alternate day until wells were filled with multinucleated OCs. TRAP
stains were employed following 10 minute fixation with 4% paraformaldehyde (Polysciences,
Warrington, PA, USA) and 0.1% Triton X-100 in PBS according to manufacturer’s instructions
(Sigma 387A, St. Louis, MO, USA).
Actin Rings
Expanded BMMS were seeded on bovine bone slices and differentiated to OCs with purified
GST-RANKL as above. At maturity, bone slices were fixed for 10 min with 4%
paraformaldehyde and 0.1% Triton X-100 in PBS, washed 3x in PBS and stained with Alexa
fluor 488 Phalloidin (Thermo Fisher Scientific A12370, Waltham, MA, UWA) for 30 min.
Slices were imaged for FITC at 20X on an Olympus BX41 fluorescent microscope.
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Resorption assay
Expanded BMMS were seeded on bovine bone slices and differentiated to OCs with purified
GST-RANKL as above. At maturity, bone slices were fixed for 10 min with 4%
paraformaldehyde and 0.1% Triton X-100 in PBS. Bone slices were incubated in 0.5 NaOH for
30 seconds and kept hydrated in PBS. Cells were scraped off bone slices with a cotton swab, and
incubated with 20µg/ml peroxidase conjugated wheat germ agglutinin in PBS (Sigma-Aldrich
61767, St. Louis, MO, USA) for 30 min. Subsequently, slices were washed 3x in PBS and
incubated with DAB chromogen kit (Biocare Medical BDB2004H, Pacheco, CA, USA) at 37˚C
for 30 min. Slices were left to dry and imaged under brightfield at 20X on an Olympus BX41
fluorescent microscope.
Quantitative real-time PCR
Following collection of cells with TRIzol (Life Technologies), solutions were centrifuged at
12,000xg and aqueous layer extracted with phenol:chloroform. An equal volume of 70% ethanol
was added, and remaining RNA isolation done via NucleoSpin RNA II kit (Clontech
Laboratories, Palo Alto, CA, USA, 740955.50). 1µg of RNA was input into cDNA Ecodry
premix kit prior to qPCR program run on ABI QuantStudio 3 with iTaq Universal SYBR Green
Supermix (Bio-Rad Laboratories 1725121, Hercules, CA, USA). Each reaction proceeded at 50˚
for 2 min, 95˚ for 10 min, then 40 cycles of 95˚ for 15 sec and 60˚ for 1 min. Relative expression
was calculated as 100*2-(target CT-B2M CT) for mouse and 100*2-(target CT-HBMS CT) for human. Primer
sequences (murine unless otherwise specified) Mfn1: F – TTGGCAGGACAAGTAGTGGC, R – AGCAGTTGGTTGTGTGACCA
Mfn2: F – AAGCACTTTGTCACTGCCAAG, R – TTGTCCCAGAGCATGGCATTG
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Human Mfn2 F – CGCGCTTATCCACTTCCCTC, R – CCAGTCCTGACTTCACCTTCC
Nfatc1: F – GGTAACTCTGTCTTTCTAACCTTAAGCTC, R –
GTGATGACCCCAGCATGCACCAGTCACA
DC-Stamp: F – ACAAACAGTTCCAAAGCTTGC, R – TCCTTGGGTTCCTTGCTTC
CatK: F –AGGCAGCTAAATGCAGAGGGTACA, R –
AGCTTGCATCGATGGACACAGAGA
B2m: F – CTGCTACGTAACACAGTTCCACCC, R – CATGATGCTTGATCACATGTCTCG
Human Hbms: F – CACCCACACACAGCCTACTT, R – CCCACGCGAATCACTCTCAT

Western blot
RIPA buffer (20mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1mM NaF) with 1:50
HALT protease and phosphatase inhibitor (Thermo Fisher Scientific 1861280, Waltham, MA,
USA) was used to lyse BMM and OC cells following 2x washes in PBS. Lysates were vortexed,
centrifuged at 700xg and supernatant quantified with BCA assay (Bio-Rad Laboratories,
Hercules, CA, USA), and 20 µg loaded to 10% SDS PAGE gel. Gels were run at 80 V for 2 hrs,
and transferred to nitrocellulose by wet transfer at 100V for 90 minutes. Blocking was done in
TBS+0.1% Tween 20 with 5% milk. Membranes were probed with 1˚ antibodies overnight at
4˚C (1:500 Mfn1 - Santa Cruz Biotechnology sc-50330, Dallas, TX, USA; 1:1,000 Mfn2 Abcam ab56889, Cambridge, UK). Actin was used as a loading control at 1:10,000 (SigmaAldrich A228, St. Louis, MO, USA). Imaging was done using SuperSignal West Femto
substrate (Thermo Fisher Scientific 34095, Waltham, MA, USA) and a chemiluminescence
imager (Syngene, Cambridge, UK).
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Retroviral overexpression
Mfn1-Myc and Mfn2-Myc were obtained from Addgene (plasmids #23212 and #23213,
respectively, Watertown, MA, USA)(Chen et al., 2003). Each gene was cloned into the pMX
retroviral vector and transfected into Platinum-E (platE) cells by calcium phosphate precipitation
(Morita et al., 2000; Zou et al., 2012). PlatE supernatant was harvested 48 and 72 hrs posttransfection, filtered through 0.45µm and added to BMMs with α-MEM, 10% FBS, and 100
IU/ml Penicillin/Streptomycin, 1:10 CMG, and 8µg/ml polybrene (Sigma H9268, St. Louis, MO,
USA) on 2 consecutive days. 24 hrs following the final viral addition, 1µg/ml blasticidin (Sigma
203350, St. Louis, MO, USA) was added to select for infected BMMs.
Seahorse
BMMs were seeded on Seahorse XF96 Cell Culture Microplates at a density of 8,000 cells/well
(cre-only and Mfn2 cKO) or 4,000 cells/well (ctrl and dcKO) in α-MEM, 10% FBS, and 100
IU/ml Penicillin/Streptomycin, 1:10 CMG. Pre-osteoclasts were treated with 30ng/ml RANKL
for 3 days. Seahorse XF Cell Mito Stress Test Kit was used according to manufacturer’s
instructions using 1µM of oligomycin, FCCP, and rotenone/antimycinA (Agilent Technologies
103015-100, Santa Clara, CA). Seahorse assay was run on Seahorse Biosciences XF96 Flux
Analyzer in the Washington University Tissue Culture Support Center.
Mitotracker
For live cell imaging BMMs were seeded onto Lab TeK II 8-well Chambered Coverglass dishes
at 40,000 cells/chamber (Thermo Fisher 155409, Waltham, MA). Following differentiation to
pre-OCs with 30ng/ml RANKL for 3 days, cells were stained with 100nM MitoTracker Green
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FM per product instructions (Molecular Probes M5714, Eugene, OR). For fixed imaging,
BMMs were seeded at 100,000 cells/well in 24-well plates containing circular coverglass
(FisherScientific 12-545-81, Hampton, NH), and differentiated with 30ng/ml RANKL. Live
mitotracker stained cells were imaged using a Nikon Spinning Disk Confocal and Nikon
Elements software at the Washington University Center for Cellular Imaging (WUCCI).
WUCCI imaging was supported by the Washington University School of Medicine, The
Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital
(CDI-CORE-2015-505) and the Foundation for Barnes-Jewish Hospital (3770).
CD14+ cell isolation
Human peripheral blood collected in sodium heparinized vacutainers was transferred to
histopaque (Ficoll Histopaque, Sigma # 10771) and centrifuged at 2,200xg for 15 min. Buffy
coat was then collected and washed twice with PBS. Per every 107 cells, cells were resuspended
in 20µl CD14 MicroBeads and 80µl MACS buffer (PBS pH7.2, 0.5% BSA, 2mM EDTA)
(Miltenyi Biotec 130-050-201, Bergisch Galdbach, Germany). Following 15 min incubation at
4˚, cells were washed and isolated via positive selection columns per manufacturer’s instructions
(LS columns: #130-042-401, MiniMACS separator kit: #130-090-312, Miltenyi Biotec, Bergisch
Galdbach, Germany). Collected CD14+ cells were plated in α-MEM (Sigma M0894, St. Louis,
MO, USA) containing 10% FBS (Gibco, Grand Island, NY, USA), 100 IU/ml
penicillin/streptomycin, 40 ng/ml hMCSF (BioLegend 574806, San Diego, CA) and 100ng/ml
RANKL for osteoclastogenesis.
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Induced osteolysis
2 month old ctrl and Mfn2 cKO animals were injected intraparitoneally (IP) with 1mg/kg body
weight GST-RANKL twice, 24 hrs apart, as previously published (Shashkova et al., 2016). 50
hrs after the first injection, animals were sacrificed.
Statistics
Two-way ANOVA with Tukey’s multiple comparisons and student’s unpaired t-tests with
Welch’s correction were performed with GraphPad Prism built-in statistical analysis (GraphPad
Software, Inc., La Jolla, CA, USA). All data are represented as mean ± standard deviation with
3+ biological replicates. P values are designated at *p<0.05, **p<0.01, ***p<0.001.
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Results
Bone mass is increased in female mice lacking Mfn1 and Mfn2 in the OC lineage
Because OCs are rich in mitochondria, we expected that disrupting mitochondrial
dynamics in these cells would manifest in global changes in bone mass. We used LysM-cre to
target OC precursors to delete Mfn1 and Mfn2. Double heterozygous (LysMc/c; (Mfn1/2)fl/+ =
ctrl) and double knockout (LysMc/c; (Mfn1/2)fl/fl = dcKO) pups were born at normal Mendelian
ratios. In parallel, double heterozygous ctrl mice were bred to cre-only (LysMc/c;(Mfn1/2)+/+)
mice to generate a cohort of ctrl and cre-only littermates.
Male and female animals were sacrificed at 2 months of age, a time of high OC activity.
Basal bone morphology was assessed by µCT of dissected femurs. We find a strong phenotype
in female animals at this age, with all trabecular and cortical parameters consistent with a high
bone mass (significantly increased BV/TV, BMD, Tb. Th., Tb. N., Cort. Th., TMD, and
decreased Tb. Sp.) (Fig. 2.1 A-B, Fig. 2.2 A-D). Interestingly, males show no significant
differences between ctrl and dcKO groups (Fig 2.1 C-D)(Fig. 2.3 A-D). Ctrl and dcKO mice
were undistinguishable by eye, and weights between groups were identical (Fig 2.2 E, Fig 2.3 E).
These data suggest that in females, mitochondrial dynamics mediated by MFN1 and MFN2
activity contribute to OC formation and/or activity. Further, bone parameters were not
significantly different between cre-only and ctrl double heterozygous mice at the same age,
indicating that loss of one allele of each mitofusin does not negatively affect the OC of either sex
in vivo (Fig. 2.2 F-L, Fig 2.3 F-L).
Serum CTX-1 levels were decreased in female dcKOs compared to ctrls, indicating an
impairment of OC activity (Fig. 2.4 A). Histomorphometry was undertaken for these same
animals to determine whether OC abundance was altered by the double knockout of Mfn1 and
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Mfn2 by LysM-cre. Although not statistically significant, the dcKO OC surface and OC number
per bone surface trend lower than ctrls (Fig 2.4 B-C). Bone accrual in this cohort was assessed
first by serum P1NP. These levels remained unchanged, suggesting a decrease in bone
catabolism alongside no change in bone anabolism for the dcKOs (Fig 2.4 D). Consistently, OB
activity is unchanged between ctrl and dcKO samples, as measured by dynamic
histomorphometry for MS/BS, MAR, and BFR/BS (Fig. 2.4 E-G). Taken together, these data
suggest that in female mice, blunted OC activity in the dcKOs is partly explained by decreases in
OC presence. However, OB-OC coupling is not affected because P1NP, MS/BS, MAR, and
BFR/BS are unchanged between groups.
Taken together, these data suggest that in female mice, loss of mitofusin activity in the
OC lineage disrupts the ability of OCs to form, and as a consequence, resorption is depressed
without affecting OB-OC coupling.
Ostoclastogenesis is inhibited in Mfn1/2 –deficient BMMs
To more closely characterize the impact of mitofusin loss in the OC lineage, BMMs were
expanded from the bone marrow of ctrl and dcKO 2 month old female mice, in which mitofusin
protein and RNA expression is decreased (Fig. 2.5). Treating BMMs with RANKL for up to 5
days to differentiate cells to OCs revealed osteoclastogenesis is defective in dcKO cultures
compared to ctrls, leading to an inability of these cells to resorb bone (Fig 2.6 A-B).
Consistently, qPCR expression of Nfatc1, DC-Stamp, and CatK are repressed in dcKOs
throughout 5 days of differentiation (Fig 2.6 C-E). We posit that this defect in
osteoclastogenesis is the primary mechanism for increased bone mass observed in dcKO female
animals.
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As in other cell types loss of mitofusin activity is associated with decreased oxygen
consumption, we analyzed female BMM and pre-OCs via Seahorse analysis. Contrary to our
expectations, no clear trends in oxygen consumption rate were discerned between genotypes in
BMM or OC samples (Fig. 2.7). However, high variability among replicates in this preliminary
assay does not allow us to make a definitive conclusion, and additional samples will be evaluated
in the future.
We sought to determine whether MFN1 or MFN2 was dominant in contributing to the
dcKO phenotype. Expression of both homologs by protein and gene expression increases as
osteoclastogenesis progresses in culture, though MFN2 to a slightly higher degree (Fig. 2.8 AB). Next we attempted to rescue the dcKO osteoclastogenesis phenotype by retrovirally
expressing either Mfn1 or Mfn2 in BMMs. We found that addition of Mfn2 to the dcKO cells
rescues osteoclastogenesis while Mfn1 does not, suggesting that MFN2 is the dominant mitofusin
homolog responsible for OC differentiation (Fig 2.2 C-E).
To further assess the difference between loss of Mfn1 or Mfn2 alone, we generated single
knockout colonies. We generated a Mfn1 cohort to assess bone parameters in cre-only and Mfn1
cKO littermates (LysMc/c; Mfn1+/+ and LysMc/c; Mfn1fl/fl, respectively). Pups were aged to 2
months and femurs collected for µCT analysis. We find no differences in trabecular or cortical
parameters in males or females at this age (Fig. 2.9). Paired with the inability of Mfn1 to rescue
dcKO osteoclastogenesis, lack of a phenotype in this cohort prompted us to discontinue further
study of the single Mfn1 cKOs.
Stress by aging and stimulated osteolysis reveals a Mfn2 cKO phenotype in vivo
To investigate whether loss of Mfn2 alone would have an effect on the OC lineage in
vivo, we generated cohorts of Cre-only and Mfn2 cKO littermates (LysMc/c; Mfn2+/+ and LysMc/c;
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Mfn2fl/fl, respectively). At 2 months of age, no differences were observed in femurs of female or
male cre-only compared to Mfn2 cKOs by mCT (Fig. 2.10 A-B). Female bones were analyzed
by historphometry and while no difference was observed between BV/TV, Oc.S/BS and
OcN./BS both trend downward in Mfn2 cKO compared to cre-only bones (Fig. 2.11).
Our group has previously observed that challenging animals with pathological bone loss
can produce robust OC phenotype even when basal changes are not present (Anginot et al., 2007;
Novack et al., 2003; Vaira et al., 2008; Wu et al., 2007). Therefore, we hypothesized this may be
the case for Mfn2 cKO animals, and explored the consequences of two models of physiological
stress in our cohort. First, we aged male and female Mfn2 cre-only and cKO mice to 4 and 12
months of age, and assessed femoral trabecular and cortical bone parameters by µCT after
sacrifice. While we observed no differences in bone parameters in either sex at 4 months when
mice exhibit peak bone mass, female Mfn2 cKOs have significantly increased trabecular bone
mass compared to cre-only animals at 12 months of age (n=9-17/group). Hence, in females, loss
of MFN2 alone in the OC lineage impacts bone resorption with aging, as the percent trabecular
bone retained from 4 months at 12 months is for 24% for ctrls and 46% for cKOs (64% and 63%
in males, respectively) (Fig. 2.10 C-F). Holistically, in females, most trabecular and cortical
parameters trend upwards in the Mfn2 cKOs, even at 2 months of age. Because no such trends
are apparent in males, we suggest that our phenotype is sex-specific (Fig. 2.12).
Next, we induced osteolysis to evaluate how OCs lacking MFN2 function when
stimulated. 2-month-old male and female control and cKO mice were challenged with
intraperitoneal RANKL injection, a model that stimulates OC activity and induces between 3050% loss in trabecular bone mass in 2 days (Fig. 2.13). Male controls, male cKOs, and female
controls lost significant amounts of bone, 30-45%, following RANKL injection. Female cKOs
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were protected from induced osteolysis, as they only appear to lose a small, but statistically
insignificant, amount of bone following treatment (Fig. 2.14-2.15). Thus, MFN2 is required for
the response of female, but not male, OCs to an acute osteolytic stimulus. The same result is
seen for stress by aging, suggesting the presence of MFN2 promotes the ability of female OCs to
resorb bone.

Loss of Mfn2 alone in the OC lineage does not reproducibly affect OC formation or function in
vitro
To probe whether loss of MFN2 impacts osteoclastogenesis in vitro, nearly 30 pairs of
cre-only and Mfn2 cKO BMMs were treated with RANKL. We find that a defect in
differentiation occurs frequently in cells harvested from 12 month old animals but less so in
those from 2 month old mice (Fig. 2.16, 2.17 A-B). Although TRAP expression levels by RNA
are not different between cre-only and Mfn2 cKO differentiating OCs from 2 month old animals,
day 4 OCs from female cKOs have significantly lower Nfatc1 expression than cre-only OCs
(Fig. 2.17 C-F). However, when these cells are grown on bone slices, no differences are seen
between bone resorption at normoxia or low oxygen conditions (Fig. 2.18 A-B). Oxygen
consumption rates are also identical between BMMs and OCs of either group (Fig. 2.18 C-F).
Despite an inconsistent defect in osteoclastogenesis between cre-only and Mfn2 cKO
cells, Mfn2 cKO pre-OCs exhibit altered mitochondria network morphology compared to creonly pre-OCs by MitoTracker green staining. The appearance of more punctate mitochondria
suggests the distance between organelles may be increased when Mfn2 is deleted from the OC
lineage (Fig. 2.19).
Mfn2 gene expression rises during osteoclastogenesis in humans
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As all of our studies thus far have been in murine cells, we isolated CD14+ monocytes
from the peripheral blood of healthy donors and exposed cells to RANKL in vitro. In assaying
Mfn2 expression in differentiated OCs we find modest increases from M-CSF-treated monocytes
to RANKL-treated OCs (Fig. 2.20). Additional samples will be required to verify whether the
increase in Mfn2 expression following OC differentiation is reproducible.
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Discussion
OCs are an incredibly dynamic cell type and during osteoclastogenesis, BMMs go
through many conformational changes including fusion of pre-OC cells to become mature
multinucleated OCs. We theorized that mitochondrial networks in differentiating OCs are
remodeled and that increased mitochondrial tethering/fusion is required for completion of this
process. To test this, we dually knocked out Mfn1 and Mfn2 in the OC lineage by Lysozyme-M
cre, finding that deletion of both homologs manifests in increased bone mass in 2 month old
female mice in vivo, which is accompanied by modest decreases in OC numbers and serum
CTX-1 levels. Further, BMMs harvested from these animals do not differentiate to OCs in vitro.
In humans, mutations in Mfn2 are most commonly associated with CMT2A. With the
severity of these neurodegenerative phenotypes, it is not surprising that the skeleton has yet to be
evaluated. While reduced mobility in these patients likely has adverse effects on the skeleton,
bone mass has not been evaluated to determine whether any changes that occur or are related to
lack of weight-bearing activity or altered MFN2 function. In other cell types, the effect of Mfn1
vs. Mfn2 knock out are not always identical, but in particular, double knock out of Mfn1 and
Mfn2 produce more severe phenotypes than single knockout of either mitofusin alone. Of note,
while cardiac specific conditional knockout of Mfn1 or Mfn2 alone display minor functional
deterioration of the heart, double deletion of Mfn1 and Mfn2 by the same cre-driver provokes
lethal cardiomyopathy (Chen et al., 2011; Papanicolaou et al., 2011; 2012a; 2012b). As a similar
situation is observed in skeletal muscle with a higher degree of muscle atrophy with double
compared to single mitofusin knockouts, we expected to observe a similar trend in the bone
(Chen et al., 2010). Like the heart and skeletal muscle, OCs are rich in mitochondria, and in
female animals, we make a comparable observation that double knockout of Mfn1 and Mfn2 in
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OC precursors halts osteoclastogenesis and ultimately begets increases in bone mass. Although
deletion of Mfn2 alone had no effect on young cohorts basally, the loss of Mfn2 in the female OC
lineage becomes protective against trabecular bone loss with age and induced osteolysis in vivo.
This is not uncommon in OC biology, as our group and others have demonstrated that despite
certain models having undetectable changes in OC activity under basal conditions, challenge by
stress and pathological bone loss produces robust OC phenotypes (Anginot et al., 2007; Novack
et al., 2003; Vaira et al., 2008; Wu et al., 2007).
To our knowledge, this is the first evaluation of mitofusin function in the OC lineage, and
expands our understanding of how these genes contribute to the formation of this specialized cell
type. Our data highlights the fact that we can no longer discount the importance of the elongated
organelles observed in human OCs by TEM and anti-mitochondria antibodies (Lemma et al.,
2016). This functional necessity of mitochondrial fusion is likely beneficial for proper OC
function as fused mitochondria in other models have been shown to prevent autophagy and allow
ATP production to be optimized due to increased cristae density favoring ATPase
oligomerization (Gomes et al., 2011; Rambold et al., 2011). While we did not observe
differences between oxygen consumption in ctrl compared to dcKO cells, we confirm that OCs
have higher oxygen consumption rates compared to BMMs, as we and others have previously
documented (Czupalla et al., 2005; Kim et al., 2007; Zeng et al., 2015).
Although we find that MFN2 alone is able to rescue the osteoclastogenesis phenotype in
dcKO cells, an OC differentiation defect is not consistently affected with loss of MFN2 alone in
the OC lineage. With functional MFN1 in the system in vitro cells derived from bone marrow of
2 month old animals maintain the ability to resorb bone and respire, indicating a compensation
effect by MFN2. The mitochondria in these cells, however, take on a striking network
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appearance in which mitotracker signal is highly aggregated. This could indicate that
mitochondrial architecture is impacted but not to a level that produces a functional response.
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Figures and tables

Figure 2.1: Trabecular and cortical bone is increased in 2 month old female mice lacking
Mfn1 and Mfn2 in the OC lineage
Female BV/TV (A) and Cort. Th. (B) is significantly elevated in dcKOs compared to ctrls by
µCT of femurs. Representative reconstructions of analyzed regions below the growth plate and
mid-shaft are shown, scale=200µm. C-D). males as in A-B. **p<0.01, unpaired t-test with
Welch’s correction.
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Figure 2.2: µCT analysis of ctrl, dcKO, and cre-only female cohorts
Additional analyses between ctrl and dcKO females at 2 months for BMD (A), Tb.N. (B), Tb.Th.
(C), Tb.Sp. (D) and weight (E). Identical analyses were undertaken for cre-only and ctrl
littermates with weight (F), BV/TV (G), BMD (H), Cort.Th. (I), Tb.N. (J), Tb.Th. (K), and
Tb.Sp. (L). **p<0.01, ***p<0.001, unpaired t-test with Welch’s correction.
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Figure 2.3: µCT analysis of ctrl, dcKO, and cre-only male cohorts
Additional analyses between ctrl and dcKO males at 2 months for BMD (A), Tb.N. (B), Tb.Th.
(C), Tb.Sp. (D) and weight (E). Identical analyses were undertaken for cre-only and ctrl
littermates with weight (F), BV/TV (G), BMD (H), Cort.Th. (I), Tb.N. (J), Tb.Th. (K), and
Tb.Sp. (L). *p<0.05, unpaired t-test with Welch’s correction.
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Figure 2.4: Female Mfn1/2 dcKOs have decreased OC numbers and activity, but no change
in bone formation
Bone turnover in 2 month old females was assessed with serum CTX-1 (A), and
histomorphometry of TRAP-stained tibiae for OC.S/BS (B) and OC.N/BS (C). Bone accrual
was assessed with serum P1NP (D), and dynamic histomorphometric analysis of unstained tibiae
for MS/BS (E), MAR (F), and BFR/BS (G). *p<0.05, one-tailed unpaired t-test with Welch’s
correction.
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Figure 2.5: Confirmation of Mfn1 and Mfn2 knockdown by western blot and qPCR
A). Protein harvested from OCs derived harvested from ctrl and cKO animals are blotted against
Mfn1 and Mfn2, and expression by qPCR is shown in (B-C). Loading controls = actin (A), B2M
(B-C), *p<0.05, unpaired t-test with Welch’s correction.
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Figure 2.6: Osteoclastogenesis is defective in BMMs derived from dcKO bone marrow.
BMMs cultured with RANKL for 5 days allow OC formation in ctrls but not in dcKOs (A), and
bone resorption is congruently inhibited in dcKOs (B). Representative images are displayed
(scale = 400µm in A, 200µm in B). OC markers NFATc1 (C), DC-Stamp (D), and CatK (E) are
blunted in dcKOs throughout 5 days of osteoclastogenesis. *p<0.05, ***p,0.001, ****p<0.0001,
unpaired t-test with Welch’s correction.
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Figure 2.7: Oxygen consumption rates in BMMs and OCs are not disrupted by loss of
Mfn1 and Mfn2
Oxygen consumption rates of ctrl and dcKO were assessed in BMM (A) and OC (B) cultures by
Seahorse analysis, n=3 biological replicates/group.
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Figure 2.8: Though both homologs increase during OC formation, addition of Mfn2 alone
drives osteoclastogenesis in vitro
A). Timecourse though 6 days of osteoclastogenesis in wild type BMMs shows increases of
Mfn1 and Mfn2 expression by protein (A) and RNA (B). C.) pMX-Vector, V, pMX-Mfn1,
Mfn1, and pMX-Mfn2, Mfn2, were retrovirally transduced into dcKO BMMs. D). Enumeration
of TRAP+ OCs staining following RANKL treatment of dcKO BMMs transduced with V, Mfn1,
or Mfn2, indicates Mfn2 but not Mfn1 alone enables OC formation, scale=400µm.
Representative TRAP-staining images are shown in (E). *p<0.05, **p<0.01, ****p<0.0001,
Two-way and one-way ANOVA with multiple comparisons in A and C, respectively.
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Figure 2.9: Bone mass of 2 month old mice is not altered when Mfn1 is lost in the OC
lineage
Femoral µCT analysis of 2 month old female mice reveals no difference between cre-only and
Mfn1 cKOs for BV/TV (A) BMD (B), Cort. Th. (C), Tb.N. (D), Tb.Th. (E), and Tb.Sp. (F).
Further, no differences in males are seen by BV/TV (G) BMD (H), Cort. Th. (I), Tb.N. (J),
Tb.Th. (K), and Tb.Sp. (L). ns=no significance, unpaired t-test with Welch’s correction.
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Figure 2.10: Female mice lacking Mfn2 alone in the OC lineage are protected from bone
loss with age
Femurs from male and female cre-only and Mfn2 cKO mice were analyzed by µCT at 2 months
(A-B), 4 months (C-D), and 12 months (E-F). *p<0.05, **p<0.01, unpaired t-test with Welch’s
correction.
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Figure 2.11: Osteoclast presence trends downward in 2 month old females lacking Mfn2 in
the OC lineage
TRAP stained sagittal tibial sections from 2 month old female mice were analyzed via
histomorphometry for BV/TV (A), Oc.S/BS (B), and Oc.N./BS (C).p-values are indicated, onetailed t-test with Welch’s correction.
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Figure 2.12: µCT analysis of cre-only and Mfn2 cKO female and male cohorts
Additional analyses between cre-only and Mfn2 cKO females at 2 months for BMD (A), Tb.N.
(B), Tb.Th. (C), Tb.Sp. (D) and Cort.Th. (E). Identical analyses were undertaken for females at
4 months (F-J), females at 12 months (K-O), males at 2 months (P-T), males at 4 months (U-Y),
and males at 12 months (Z-DD). *p<0.05, unpaired t-test with Welch’s correction.
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Figure 2.13: acute osteolysis model
A). Schematic of protocol with VivaCT scan one day prior to first RANKL injection. A second
RANKL injection is administered 24 hrs after the first, and mice are sacrificed 50 hours after the
first injection. B). Pilot B6 animals were scanned pre- and post-treatment, and lose trabecular
bone volume. *p>0.05, unpaired t-test with Welch’s correction.
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Figure 2.14: Female mice lacking Mfn2 in the OC lineage are protected from acute
osteolysis
A model of acute bone loss by RANKL injection performed on 2 month old cre-only and Mfn2
cKO mice induces significant bone loss in all males, cre-only females, but not Mfn2 cKO
females (A-B). C). Representative post-RANKL µCT reconstructions from A-B, scale=200µm.
*p<0.05, **p<0.01, ordinary two-way ANOVA with multiple comparisons.
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Figure 2.15: µCT analysis of induced osteolysis in female and male cohorts
Additional analyses between cre-only and Mfn2 cKO females with no treatment or acute
RANKL challenge for BMD (A), Cort.Th. (B), Trab.N. (C), Trab.Th. (D), and Trab.Sp. (E).
Identical analyses for males are shown in F-J. *p<0.05, **p<0.01, ordinary two-way ANOVA
with multiple comparisons.
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Figure 2.16: Confirmation of Mfn2 knockdown by western blot and qPCR
A). Protein harvested from OCs derived from cre-only and Mfn2 cKO animals are blotted
against Mfn2, and expression by qPCR is shown in (B). *p<0.05, unpaired t-test with Welch’s
correction.
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Figure 2.17: Loss of Mfn2 in the OC lineage does not consistently impede osteoclastogenesis
by TRAP and gene expression
A). Representation of experiment yielding defect in OC formation when Mfn2 is deleted in the
OC lineage and percentage of this phenotype occurring in samples derived from bone marrow of
2 and 12 month old animals. B). Representation of experiment yielding no defect in OC
formation when Mfn2 is deleted in the OC lineage and percentage of this phenotype occurring in
samples derived from bone marrow of 2 and 12 month old animals. In differentiating OCs from
2 month old bone marrow Nfatc1 (C-D) and TRAP (E-F) expression are assessed by qPCR (n=4
biological replicates per group), *p<0.05, two-way ANOVA.
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Figure 2.18: Lack of Mfn2 in the OC lineage does not affect bone resorption or oxygen
consumption.
Pit staining after cre-only and Mfn2 cKO BMMs were differentiated on bovine bone slices in
20% O2 (A) or 5% O2 (B). Female BMMs (C) and OCs (D) were analyzed by Seahorse analysis.
Males in E-F.
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Figure 2.19: Pre-OCs lacking Mfn2 display altered mitochondrial networks compared to
cre-only pre-OCs
BMMs from cre-only and Mfn2 cKO mice were differentiated with RANKL and stained with
Mitotracker Green to illuminate mitochondria. Image are 100X.
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Figure 2.20: Mfn2 expression increases from human monocytes to OCs in vitro.
A). CD14+ cells isolated from human peripheral blood differentiated to mature OCs are shown
via brightfield microscopy at 4X B). Mfn2 expression was assayed by qPCR in two patient
samples and is increased in RANKL-treated OCs compared to CD14+ precursors.
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Chapter 3 –
Tethering function of Mfn2 is required for osteoclastogenesis in vitro
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Introduction
In this chapter, we aimed to determine which function of MFN2 is responsible for
promoting osteoclastogenesis. One function of MFN2 is to promote tethering of mitochondria to
mitochondria and mitochondria to the ER, leading to mitochondrial fusion and altered signaling
such as Ca2+, respectively. The other function of the protein is to stimulate PINK1/PARKIN
signaling to remove defective organelles via mitophagy. In non-OC-forming Mfn1/2 dcKO
BMMs, we overexpress mutants that selectively disable tethering (Mfn2-EE) or mitophagy
(Mfn2-AA). We show that in this cell lineage, tethering/fusion by MFN2 is required for OC
differentiation. Because Ca2+-dependent Nfatc1 levels are decreased in our Mfn2 cKO cells,
further experiments are undertaken to begin probing whether MFN2-mitochondria tethering and
subsequent Ca2+ signaling plays a role in our system. While work in this area is still ongoing, we
are confident that the specific role of MFN2 is crucial and possibly unique in the OC compared
to other cell types. We are determined to elucidate this mechanism in future studies beyond the
scope of this dissertation.
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Materials and methods
Retroviral overexpression
Mfn2-WT, Mfn2-EE, and Mfn2-AA were gifts from Gerald Dorn II, M.D. (Washington
University in St. Louis). Each gene was cloned into the pMX retroviral vector and transfected
into Platinum-E (platE) cells by calcium phosphate precipitation (Morita et al., 2000; Zou et al.,
2012). PlatE supernatant was harvested 48 and 72 hrs post-transfection, filtered through 0.45µm
and added to BMMs with α-MEM, 10% FBS, and 100 IU/ml Penicillin/Streptomycin, 1:10
CMG, and 8µg/ml polybrene (Sigma H9268, St. Louis, MO, USA) on 2 consecutive days. 24
hrs following the final viral addition, 1µg/ml blasticidin (Sigma 203350, St. Louis, MO, USA)
was added to select for infected BMMs. Retroviral NFATc1-WT and NFATc1-CA were
acquired from Addgene (plasmid #11101 and #11102, respectively, Watertown, MA,
USA)(Monticelli and Rao, 2002).
Mitotracker staining
BMMs were seeded at 100,000 cells/well in 24-well plates containing circular coverglass
(FisherScientific 12-545-81, Hampton, NH), and differentiated with 30ng/ml RANKL. Prior to
fixation, cells were washed once with PBS and stained with 100nM Mitotracker Deep Red FM
per product instructions (Molecular Probes M22426, Eugene, OR). Wells were then fixed with
4% paraformaydehyde for 10 min, and coverglass adhered to slides with ProLong Diamond
Antifade Mountant with DAPI P36962 (Invitrogen, Carlsbad, CA). Slides were imaged using a
Zeiss LSM 880 Confocal with Airyscan with 63x magnification and optical zoom of 1.8 at the
Washington University Center for Cellular Imaging (WUCCI). WUCCI imaging was supported
by the Washington University School of Medicine, The Children’s Discovery Institute of
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Washington University and St. Louis Children’s Hospital (CDI-CORE-2015-505) and the
Foundation for Barnes-Jewish Hospital (3770).

Ca2+ Oscillations
BMMs seeded on 29 mm glass bottom dish at a density of 300,000 cells/dish, and exposed to
30ng/ml RANKL for 2 days. Dishes were washed in 1X HBSS containing 1 mM Mg2+ and 2
mM Ca2+, then stained with the same buffer and 2µM Fura-2 AM and 10 ng/ml hMCSF for 30
min at 37˚C (Life Technologies F-1221, Carlsbad, CA, USA; BioLegend 574806, San Diego,
CA, USA). Following three washes with 1X HBSS containing 1 mM Mg2+, cells were kept in
this buffer with additional 10ng/ml hMCSF. Ratiometric Ca2+ was performed with a Till
Photonics digital microscope at the Center for Investigation of Membrane Excitability Diseases
(CIMED) Live Cell Imaging Core (Washington University in St. Louis). 100uM and 2 mM
CaCl2 were added following baseline collection to induce increases in cytosolic Ca2+ when data
is presented as 240/380 ratios.
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Results
Mitochondrial tethering is the dominant Mfn2 mechanism contributing to osteoclastogenesis in
vitro
MFN2 has two main molecular functions – tethering and mitophagy – that can be
selectively disabled via mutation to examine the ability of either to impact OCs. As we
consistently observe a decrease in osteoclastogenesis in cells derived from female dcKO bone
marrow, we infected these BMMs with each of the following retroviral constructs: Vector,
Mfn2-WT, Mfn2-EE (T11E-S442E; defective tethering due to spontaneous mitophagy without a
fusion signal), and Mfn2-AA (T111A-S442A; defective mitophagy without impacting
fusion)(Gong et al., 2015). Cultures were stained for TRAP as OC differentiation progressed.
We find that transduction of dcKO BMMs with Mfn2-AA restores osteoclastogenesis to a
comparable level as Mfn2-WT, indicating that the mitophagy function of MFN2 is dispensable
for osteoclastogenesis. In contrast, transduction with Mfn2-EE has only a modest effect on
osteoclastogenesis, suggesting that tethering is necessary for osteoclastogenesis to occur (Fig.
3.1). When assessing mitochondrial networks by Mitotracker Red staining, however, gross
differences between staining in Mfn2-EE and Mfn2-AA are not observed. Here, mitochondria
display a rather intermediate phenotype between densely aggregated mitochondria in Vector
cells and uniformly organized organelles in Mfn2-WT cells (Fig. 3.2). This implies fusion of
mitochondria partially accounts for MFN2 support of osteoclastogenesis, and that tethering may
play a greater role.
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Tethering defect does not impact Nfatc1 through a mitochondrial calcium buffering mechanism
Because tethering of MFN2 promotes mitochondria-mitochondria interactions as well as
mitochondria-ER interactions, we hypothesized that ER-mitochondria proximity is important for
OC formation, as this is an exclusive function of MFN2 that MFN1 does not share. This appears
plausible because oscillation in cytosolic Ca2+ is known to regulate Nfatc1 induction, and we
detect significantly decreased Nfatc1 levels in OCs from Mfn2 cKO and Mfn1/2 dcKO compared
to cre-only and ctrls, respectively (Fig. 2.6 and Fig. 2.17) (Hogan et al., 2003; Kim et al., 2013).
Previously, we tried to rescue the osteoclastogenesis defect seen in Mfn2 cKO BMMs derived
from 12 month old animals by overexpressing Nfatc1. Irrespective of RANKL dose used, TRAP
staining of Mfn2 cKO cells treated with Nfatc1 was identical to those infected with the vector
control (Fig. 3.3). This result, however, did not exclude the possibility that NFATc1 localization
the nucleus was impaired.
To assess whether Ca2+-dependent regulation of NFATc1 targeting to the nucleus was
impacted by Mfn2 loss in BMMs, dcKO BMMs were infected with wild type (WT) or
constitutively active (CA) forms of Nfatc1 and treated with RANKL. In two independent
experiments pilot experiments, while no striking differences between WT and CA are seen, we
cannot discount the observation that CA OCs counts per well are elevated compared to WT (Fig.
3.4). Lack of effect could be attributed to the fact that lack of a mammalian selection gene in
these vectors did not allow elimination of uninfected BMMs prior to addition of RANKL. We
are currently working to clone these genes into a selectable vector as well as collect protein for
NFATc1 western blot to definitively conclude the effect of WT vs. CA Nfatc1 in our in vitro
system.
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To further explore Ca2+ signaling in the model, cytosolic Ca2+ was measured via
ratiometric imaging in one pilot experiment. Here, although ctrl pre-OCs may appear to have
higher amplitude in oscillations, we cannot claim any definitive differences are consistent seen
between groups (Fig. 3.5). We note that this is one trial, and due to difficulty placing ATP and
Ca2+ stimuli directly in the line of the camera, another trial of this experiment is needed before
ruling out the possibility of differing Ca2+ handling when mitofusins are deleted in the OC
lineage.
In another effort to examine wither Mfn2-directed mitochondrial tethering to the ER is
responsible for decreased osteoclastogenesis in our dcKO cells, two additional retroviral Mfn2
mutants were constructed. First, an Italian group recently identified a substitution mutation in
MFN2, K416R, that disrupts the mitochondria-ER distance and mitochondrial Ca2+ uptake
(Basso et al., 2018). However, this study does not explicitly assess whether mitochondrial fusion
is disrupted with MFN2 K416R mutation, though we infer from seemingly networked images
that mitochondria-mitochondria tethering and subsequent fusion is not affected in this model.
Nevertheless, lack of such specific information means our osteoclastogenesis results to be
interpreted with caution. We cloned this mutant and overexpressed it in dcKO BMMs via
retroviral infection. No differences in OC formation are seen between cells with overexpressed
Mfn2-WT and Mfn2-K416R in our standard OC formation assay (Fig. 3.6). Here, these results
suggest that impaired ER-mitochondria tethering by MFN2 in the OC may not be the mechanism
sole mechanism that drives OC formation.
Second, in vitro assays using Mfn2-F223L mutation in MEFs revealed that this mutant
has normal ability of mitochondria to tether into dimers, but have impaired homotypic fusion of
Mfn2-F223L to Mfn2-F223L mitochondria, even when Mfn1-WT is present in the system, due
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to a potential defect in GTP hydrolysis disallowing nucleotide-dependent self-assembly of the
MFN2 molecules (Daumke and Roux, 2017; Engelhart and Hoppins, 2019). Though it is not
clear whether this applies to MFN2 on the ER membrane, the data suggest that association of
Mfn2-F223L proteins is not affected. Retroviral overexpression of Mfn2-F223L in dcKO
BMMs does not promote osteoclastogenesis, indicating that solely tethering but not fusion of
MFN2 may be dispensable in the OC lineage (Fig. 3.7).
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Discussion
We sought to determine the mechanism through which mitofusin activity contributes to
OC formation. Because we see that high bone mass phenotypes in knockouts compared to
littermate controls in our animal models are more pronounced in Mfn1/2 dcKOs than Mfn1 or
Mfn2 cKOs, this could suggest that the effect on the OC lineage is solely an effect of mitofusin
dose. Here, loss of one homolog could be compensated for by the presence of the other in single
Mfn1 and Mfn2 cKO animals. This does not, however, explain why overexpression of Mfn2 but
not Mfn1 rescues osteoclast formation in vitro. We therefore postulated that MFN2 contributes
in a way that MFN1 cannot. MFN2-specific functions include initiation of mitophagy, following
phosphorylation of MFN2 by PINK, and regulation of mitochondrial-ER interactions, a
consequence of tethering. Our demonstration that overexpressing Mfn2-AA (defective
mitophagy) but not Mfn2-EE (defective fusion) rescues osteoclastogenesis pointed us toward
mitochondria-ER interactions as a possible mechanism.
MFN2 is present not only on the outer mitochondrial membrane, but on the ER
membrane, facing the cytoplasm. Interactions between ER-located MFN2 with mitofusins on
mitochondria control the proximity of these two organelles (Filadi et al., 2018b). Mitochondrial
tethering to the ER by MFN2 is known to specifically regulate cellular functions such as Ca2+
signaling and the ER stress response (reviewed in (Filadi et al., 2018a; van Vliet and Agostinis,
2018). Studies using Mfn2 knockdown cells have revealed that loss of Mfn2 is associated with
increased distance between the mitochondria and ER as well as impaired mitochondrial Ca2+
uptake, which hinders calcineurin and apoptosis pathways (de Brito and Scorrano, 2008;
Karbowski et al., 2006; Kasahara et al., 2013; Naon et al., 2016). Here, because the decreased
Nfatc1 levels we observe in Mfn1/2 dcKO and Mfn2 cKO OCs in vitro directly implicate Ca2+
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signaling in our cultures, we postulate that changes in Ca2+ may be the link to decreased OC
formation in our model. Although Ca2+ oscillations in ctrl and dcKO cells were not grossly
different in a pilot experiment of n=1/group and overexpression of Nfatc1-CA did not wholly
imprive osteoclastogenesis over Nfatc1-WT in mitofusin-deficient dcKO BMMs, future studies
in the laboratory will probe these with additional rigor. This will include measuring changes in
mitochondrial Ca2+ in addition to cytosolic Ca2+ when Mfn2 presence is altered, and repeating
rescue experiments using selectable Nfatc1-WT and Nfatc1-CA vectors.
Our in vitro investigation of MFN2 mutations K416R and F223L could naively imply
that tethering of adjacent MFN2 molecules either between neighboring mitochondria or
mitochondria and the ER is not necessary for OC differentiation. Here, disabling ERmitochondria tethering with K416R did not inhibit osteoclast formation, and disabling fusion
while leaving tethering intact with F223L produced no OCs. Accepting these data would prompt
us to conclude that fusion between mitochondria is the primary mechanism through which
mitofusins support osteoclastogenesis, at least in culture. This simplistic interpretation however
does not consider the fact that both of these mutants were primarily evaluated by others solely in
MEF cells and in purified mitochondrial fractions lacking a native cell environment. Mutants
could plausibly behave differently in the context of a differentiating OC and more work is
needed to further probe the effect of these substitution mutations.
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Figures and tables

Figure 3.1: Restoration of Mfn2 tethering function restores osteoclastogenesis in dcKO
BMMs
A). dcKO BMMs were transduced with retroviral pMX-Vector, V, tethering-defective mutant
pMX-Mfn2-EE, EE, and mitophagy defective pMX-Mfn2-AA, and Mfn2 protein detected via
western blot. B). While Mfn2-EE allows mitophagy, Mfn2-AA allows tethering/fusion. C).
Cultures were TRAP-stained following 6 days of RANKL exposure. OC numbers are quantified
in D. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ordinary one-way ANOVA.
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Figure 3.2: Mitochondrial fusion is modestly altered with overexpression of Mfn2 mutants
in vitro
Following transduction pMX-Vector, V, pMX-Mfn2-WT, WT, pMX-Mfn2-T111EE-S442E, EE,
and pMX-Mfn2- T111A-S442A, AA, into dcKO BMMs and treated with RANKL, pre-OCs
were stained with Dapi and Mitotracker Red. Mitochondrial networks are illuminated, scale =
7µm.
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Figure 3.3: Nfatc1 overexpression does not rescue osteoclastogenesis defect in BMMs
derived from 12 month old Mfn2 cKO mice
Cre-only and Mfn2 cKO BMMs harvested from 12 month old animals were infected with empty
vector or Nfatc1 and cultured with RANKL. Representative TRAP images are shown over a
number of days and RANKL doses at 2X.
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Figure 3.4: Wild type and constitutively active Nfatc1 induce osteoclastogenesis to the same
degree in dcKO BMMs.
A). dcKO BMMs were infected with a retroviral vector, Nfatc1-WT, or Nfatc1-CA, and stained
for TRAP. Osteoclast numbers are shown in (B). Representative images from both trials are
shown at 2X.

72

Figure 3.5: No differences are seen in basal Ca2+ oscillations between ctrl and dcKO cells
Female ctrl and dcKO BMMs and OCs were loaded with Fura-2 dye and cytosolic calcium
measured over time. Basal represents oscillations prior to ATP or CA2+ stimuli.
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Figure 3.6: Disabling Mfn2 tethering to the ER does not impact osteoclastogenesis.
A). Female dcKO BMMs were retrovirally infected with the overexpression of vector, Mfn2WT, or Mfn2-K416R, treated with RANKL, and TRAP stained. Number of OCs per well are
plotted in (B).
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Figure 3.7: Restoring tethering but not fusion functions of Mfn2 does not support
osteoclastogenesis.
A). Female dcKO BMMs were retrovirally infected with the overexpression of vector, Mfn2WT, or Mfn2-F223L, treated with RANKL, and TRAP stained. Number of OCs per well are
plotted in (B).
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Chapter 4 –
Discussion and future directions
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Part 1 – Role of mitofusins in the OC lineage
Our data reveals that mitofusin activity is an important component of OC formation in
vivo and in vitro. In murine models, dual loss of Mfn1 and Mfn2 causes a high bone mass
phenotype in female animals, and single loss of Mfn2 offers protection from bone loss with age
and induced osteolysis in females. In culture, expression of Mfn2 on a double Mfn1/Mfn2
knockout background induces osteoclastogenesis to a greater degree than Mfn1. Further,
selectively disabling the mitophagy function of MFN2 has no effect on OC formation, but
osteoclastogenesis is impaired when the tethering ability of MFN2 is ablated. Therefore,
because OC differentiation ensues when solely MFN2, but not MFN1, is present, we hypothesize
MFN2 must have a non-redundant function from MFN1 that allows this to occur. This could be
the unique ability of MFN2 to tether mitochondria to the ER, because changes in ER-MFN2
juxtaposition are known to modulate cytosolic Ca2+ levels (Naon et al., 2016). In turn, Ca2+
modulates translocation of NFATc1 to the nucleus, and our dcKO and Mfn2 cKO have
decreased Nfatc1 expression (Hogan et al., 2003). However, our mechanistic studies thus far
have not been able to confirm or refute the hypothesis that abnormal ER-MFN2 juxtaposition in
our knockouts alters Ca2+ handling and therefore reduces NFATc1-driven OC differentiation.
In assessing the effect of Mfn2-K416R and Mfn2-F223L mutations in vitro, preliminary
experiments suggest that Mfn2 association with the ER does not have an effect on
osteoclastogenesis, because dcKO cells overexpressing Mfn2-K416R (mutant that disables
mitochondria-ER tethering) generate mature OCs. Conversely, and when Mfn2-F223L (mutant
that allows tethering but inhibits fusion) is added, the ability of BMMs to differentiate to OCs is
abolished. It remains unclear, however, in the original studies of these mutants whether Mfn2K416R permits mitochondrial fusion or whether the tethering ability of Mfn2-F223L relates to
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ER-mitochondria relationship in addition to mitochondria-mitochondria interactions. Answering
these questions is imperative to fully assess and interpret the effect of these mutants in our
system. To begin additional characterization of these mutations, retroviral rescue experiments
will be repeated in a single Mfn2 cKO background to evaluate whether K416R and F223L
mutations have different effects when interactions with endogenous MFN1 are allowed. Future
exploration will also include study of [Ca2+] in the cytoplasm and mitochondria of pre-OCs with
varying MFN2 mutations to determine whether changes in mitochondrial juxtaposition to the ER
with K416R mutation culminates in biologically meaningful changes in signaling on the Ca2+
/NFATc1 axis. It could also be the case that decreases in dcKO and Mfn2 cKO Nfatc1
expression is due to Ca2+-independent mechanisms. Because changes in Ca2+ oscillations that
affect NFATc1 might be difficult to detect, EM microscopy can be simultaneously employed to
precisely measure ER to mitochondria distances in our cells and understand how tethering
changes by Mfn2 may impact osteoclastogenesis.
We cannot rule out that Mfn2 activity in vitro may not be indicative of how the protein
operates in vivo, and that tethering/fusion of MFN2 could alter OC function in addition to or
instead of OC differentiation when in a biological setting. In particular, in vitro
osteoclastogenesis phenotypes are inconsistent between BMMs derived from cre-only and Mfn2
cKO animals. We have assessed whether in vivo and in vitro phenotypes are correlated, but
BMMs derived from high bone mass animals are not consistently defective in OC formation (R.
Zeng, unpublished observation).
Critical interpretation could be attained through generating knock-in mice harboring the
Mfn2-K416R or Mfn2-F223L mutations. Knock-in of mutations to the Rosa26 locus would
allow cre-driven induction and overexpression of Mfn2 mutants in OC lineage cells at birth, or
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genes could be activated or deleted at different stages with incorporation of rtTA or diphtheria
toxin transgenes, respectively (Belteki et al., 2005; Ivanova et al., 2005). This would allow
tighter control of expression during murine development or experimental timelines.
Alternatively, allowing Mfn2 mutations to be expressed and regulated at physiological levels
through global CRISPR-mediated point mutations could offer relevant and powerful study of
disabled ER juxtaposition and tethering by MFN2. Combining such knock-ins of K416R and
F223L on a background in which Mfn1 is deleted in the OC lineage might have further potential
to dissect this specific role of Mfn2 tethering on bone mass.
Additional options could include crossing cKO or Mfn2 mutation-containing animals
with those harboring fluorescent mitochondria to further assess changes in mitochondrial
architecture during osteoclast formation (Pham et al., 2012; Sun et al., 2015). In particular,
mitochondrial fusion maybe evaluated in vivo using PhAMexcised animals in which mitochondria
constitutively express GFP unless exposed to 405 nm laser light where they express RFP. By
exposing sub-populations of mitochondria to light, fusion events of green and red organelles may
be characterized by yellow fluorescence (Pham et al., 2012). Differentiating BMMs from these
animals would allow quantification and comparison of fusion events when different Mfn2
mutants are introduced in vitro.
An unexplored area in this thesis is additional signaling pathways in which MFN2 is
involved. For example, mTOR is reported to be enriched in the mitochondria-associated ER
membranes (MAM), and its activity is suppressed when bound by the HR1 domain of MFN2
(Betz et al., 2013; Xu et al., 2017). This in turn inhibits mTORC2 signaling through PI3K and
Akt (Xue et al., 2018). Intriguingly other groups have demonstrated that inhibition of mTOR
and downstream Akt signaling supports OC formation and survival in animal and cell culture
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models (Dai et al., 2017; Glantschnig et al., 2003; Sugatani and Hruska, 2005; Tiedemann et al.,
2017). It is tempting to speculate that without the tethering function of MFN2 linking
mitochondria to the ER in the OC, the MAM is disrupted and therefore hinder OC differentiation
via lack of MTORC2 activity.
Wnt signaling might also have implications in MFN2 activity as our laboratory finds
increased β-catenin protein levels in OBs with conditional deletion of Mfn2 compared to controls
(A. Zarei, unpublished observation). This correlates with increased osteogenesis we see in vitro
from bone marrow stromal cells lacking Mfn2 and increased mitochondrial activity that others
have documented (An et al., 2010; Shares et al., 2018). If β-catenin levels are altered in our OC
model as well, disruption of β-catenin protein regulation by MFN2 could be detrimental to OC
formation. β-catenin decreases OC through direct inhibition of RANKL-induced NF-κB signals
and Nfatc1 induction in the OC (Kobayashi et al., 2016; Lerner and Ohlsson, 2015; MovérareSkrtic et al., 2014; Shares et al., 2018). Moreover, glycolytic enzyme pyruvate kinase (PKM2)
was recently shown to interact with MFN2 downstream of mTOR to not only promote
mitochondrial fusion, but also attenuate glycolysis while stimulating OxPhos (Li et al., 2019).
We cannot rule out the possibility that inability of MFN2 to associate with PKM2 in the OC
could singularly disrupt mitochondrial fusion and normal metabolic properties of this cell type.
Future studies will probe the relationship between MFN2 and MTORc2, β-catenin, and
PK2M in the OC lineage. We will start by conducting in vitro timecourse experiments to
determine how RNA and protein expression of these factors change during osteoclastogenesis in
BMMs derived from ctrl and dcKO bone marrow. Anticipating MTORC2, β-catenin, and/or
PK2M expression will change with MFN2 levels during osteoclastogenesis, we can move
forward in activating or disabling these components in the presence or absence of Mfn2.
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Because knockdown of PK2M increases mitochondrial fragmentation, we could also try rescuing
mitofusin deficiencies with PKM2 overexpression in vitro (Li et al., 2019). Such experiments
have the potential to pinpoint how MFN2 converges with other signaling pathways to support
OC formation in our model.
We are intrigued by the striking sexual differences in our model, and to our knowledge
this is the second report of differences in male vs. female response to mitofusin loss. Conditional
ablation of Mfn2 in brown adipose tissue (BAT) leads to dysfunction of the tissue and protection
from insulin resistance and obesity by high-fat diet. Here, a sex-specific remodeling of BAT
mitochondrial function was reported after Mfn2 deletion as females displayed increased ATPsynthesizing fat oxidation while males experienced increased glycolytic capacity (Boutant et al.,
2017; Mahdaviani et al., 2017). This suggests that female mitochondria may have an inherent
bias toward oxidative phosphorylation over glycolysis in the bone, and with the induction of
stress, tethering-compromised mitochondria may be unable to respond and accommodate to
stress by maximizing ATP output through efficiently fusing OMM and IMM. As mitochondrial
differences in male and female mammals have been documented in other organs, is it
unsurprising that this also manifests in the OC lineage. For example, female murine
cardiomyocyte mitochondria are more efficient than male cells despite having lower
mitochondrial content (reviewed in (Ventura-Clapier et al., 2017)). Sex differences in
mitochondria can plausibly be due to the fact that mitochondrial DNA is only under selection in
females, therefore allowing hormones like estrogens to have a protective effect on female
mitochondria.
Intriguingly, a major regulator of the OC is estrogen. In menopause, estrogen production
by the ovaries falls and leads to increased bone resorption by the OC. Estrogen deficiency
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reverses the pro-apoptotic effect of the molecule on the OC and enables upregulation of TNFα
and IL-1β cytokines as well as RANKL that promote OC differentiation. Estrogen deficiency
also disfavors the commitment of mesenchymal progenitors to the OB lineage and fails to block
OB apoptosis, further leading to the overabundance of OC activity and bone resorption in postmenopausal women (reviewed in (Khosla et al., 2011; Novack, 2010). Congruently, we theorize
that sex differences in our model may be inherent to OC biology. We have previously observed
that compared to males, female mice have more numerous OCs in the trabecular compartment
compared to males (Zarei et al., 2018). We anticipate that a higher abundance of OCs might
make females more susceptible to the impact of mitochondrial defects in the cell lineage. It
would be interesting to further investigate the role of estrogen in mitochondrial dynamics.
Depletion of estrogen with ovariectomy (OVX) surgeries could determine if estrogen is
responsible for female phenotypes. If so, we would expect Mfn2 cKO females post-OVX to
have identical bone mass to ctrls post-OVX, similar to how males respond to loss of bone mass
with RANKL-injection. We could consider approaching the interplay of estrogen and MFN2 in
culture by supplementing culture media with or without estrogen, and undertaking transcriptional
profiling of cellular populations. In vivo, laser capture microdissection of frozen skeletal tissues
would allow isolation of male or female OCs and confirmation of differences observed in vitro.

Part 2 – Final comments
In sum, our studies highlight the importance of mitochondrial tethering/fusion in OC
lineage cells and bring the skeleton into light for the field of mitochondrial dynamics. With
continued investigation, our work opens the possibility that regulation of mitochondrial
dynamics in the osteoclast could modulate bone mass in humans. Especially as women are more
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prone to osteoporosis then men, altering mitofusin activity has the potential to be exploited for
preservation of bone mass in this post-menopausal population.
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Appendix A –
Transcription Factor EB
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Abstract
In 2011, a 3-year old boy born to consanguineous parents presented to physicians at
Shriners Hospitals for Children in St. Louis with clinical signs of osteopetrosis (OPT). His
bones were abnormally dense, as reflected by a lumbar spine z-score of +13.4. A bone core
biopsy of the dsistal metaphasys of the tibia revealed the abundance of OBs and a complete
absence of OCs. Active bone formation by tetracycline labeling along with a disorganized
trabecular compartment suggested the patient presented with OC-poor OPT (Fig. A.1). Further,
RANKL-stimulated peripheral blood monocytes formed few mature TRAP+ multinucleated OCs
that lacked actin rings in vitro (Fig. A.2). Failure of OC differentiation in this assay revealed that
the defect was inherent to cells of hematopoietic origin because the addition of recombinant
RANKL did not drive OC formation. The patient-derived cells produced full-length RANK
protein, and sequencing revealed the genes that encode RANK and RANKL to be wild type.
Interestingly, all other OPT-associated genes were sequenced, and no abnormalities were found.
Whole exome sequencing of this OC-poor OPT patient and his parents revealed a
homozygous missense mutation in Transcription Factor EB, Tfeb, S401N, a transcription factor
previously implicated in modulating OC bone resorption through disruption of lysosomal
biogenesis. The goal of this study was to enhance our understanding of how Tfeb relates to OC
formation as well as function, and investigate the link between this transcription factor and
osteopetrotic phenotypes humans.
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Introduction
Osteopetrosis (OPT):
Alteration of OC differentiation or function that is not matched by OB activity leads to a
shift in bone composition toward low bone mass osteoporosis or high bone mass osteopetrosis
(OPT), both of which have detrimental effects on skeletal health and quality of life for patients.
Historically, OPT is attributed to mutations in a limited set of genes involved either in OC
formation or function that contribute to OC-poor or OC-rich forms of the disease, respectively.
Whether due to the absence of OCs or the presence of dysfunctional OCs, the ultimate
phenotypic result is a failure of bone resorption that is associated with a set of clinical
observations, including altered bone modeling, brittle bones prone to fracture, and anemia and
bone marrow failure. Severe forms of OPT present in early childhood and are often fatal in early
years as the bone marrow cavity is overcome by excess bone formation. In cases when the OPTcausing defect is intrinsic to the OC, bone marrow transplant can be an effective treatment to
replace these cells of hematopoietic origin (reviewed in (Sobacchi et al., 2013)).
Whole exome sequencing (WES) was undertaken in our family from Shriners Hospitals
for Children in St. Louis, and a small pool of candidate genes segregated with the homozygous
inheritance pattern in the affected child and his parents. Two of the genes, Rab6c (a member of
the Ras oncogene family) and Ubr5 (an E3 ubiquitin ligase), are not associated with bone
biology in the literature. A third, however, was a missense mutation in Transcription Factor EB
(Tfeb), a gene previously implicated in OC biology. While homozygous in the patient, the
mutated Tfeb allele was heterozygous in both parents and absent in his unaffected sister. The
particular mutation, S401N, falls within a relatively uncharacterized domain of the transcription
factor (Fig. A.3). This serine residue is well conserved in mammals, birds, and reptiles, but not
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fishes and amphibians. Evidence by mass spectrometry suggests that this serine residue is not
phosphorylated (correspondence with Marco Sardiello, Ph.D.).

Transcription Factor EB (Tfeb):
Transcription Factor EB (Tfeb) is a highly conserved master regulator of lysosomal
biogenesis and autophagy. In response to environmental cues, Tfeb is regulated posttranslationally via sequestration in the cytoplasm or release into the nucleus. Here, under basal
conditions it is localized to lysosomal surfaces by interaction with the lysosome nutrient sensing
(LYNUS) machinery and phosphorylated by mammalian target of rapamycin complex 1
(mTORC1) on N-terminal residues S142 and S211 (Settembre et al., 2012). Upon mTORC1
inactivation due to cellular stress, starvation, or lysosomal inhibition, Tfeb becomes
dephosphorylated and translocates to the nucleus to activate coordinated lysosomal expression
and regulation (CLEAR)-network genes involved in lysosomal biogenesis and autophagy as well
as amplify its own signal (reviewed in (Settembre et al., 2013)).
Another recently identified mechanism of post-translational Tfeb regulation in murine
models relies on phosphorylation of several residues on the C-terminal end of the protein.
Downstream of RANK signaling, these modifications by PKCβ are believed to stabilize Tfeb
and facilitate nuclear translocation and therefore upregulation of lysosomal biogenesis factors.
In the same murine model system, conditional deletion of Tfeb late in the OC lineage by
cathepsin K-cre was associated with increased bone mass but unaltered OC number. Here, lack
of Tfeb in OCs contributes to a high bone mass phenotype in mice through insufficient
acidification of the OC resorption lacuna through decreased transcription of Tfeb target genes
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required for lysosome formation, including H+ ATPase and chloride channel subunits (Ferron et
al., 2013).
Tfeb belongs to the Mitf family of four basic helix-loop-helix-leucine zipper (bHLH-Zip)
transcription factors that regulate gene expression by binding to E-box regions as hetero- or
homo-dimers. One family member, Mitf, is thought to modulate NFATc1 activity to promote
osteoclast function downstream of RANK signaling (Lu et al., 2014). In vivo, dominant negative
mutations in Mitf are associated with osteopetrotic phenotypes. These mutations disrupt residues
that fall within the basic and helix-loop-helix domains of Mitf important for DNA binding, and
murine femurs display excessive endochondral bone and lack a bone marrow cavity. These same
mutations also hinder heterodimerization of Mitf with Tfe3 to eliminate Tfe3-DNA interactions
in vitro, and OCs from these mice are small and stain weakly for TRAP compared to controls by
histology. Interestingly, such phenotypes are not observed with Mitf of Tfe3 null mutations, but
only in combined Mitf/Tfe3-null animals, or those harboring a dominant negative allele
(Hemesath et al., 1994; Steingrimsson et al., 2003; 2002). It seems likely that a similar situation
might occur with Tfeb. Complete disruption of Tfeb results in embryonic lethality in mice
between E9.5-E10.5 due to defects in placental vascularization (Steingrímsson et al., 1998).
Phenotypes are not observed in animals heterozygous for Tfeb loss in combination with Tfe3,
Tfeb, or Mitf mutations. However, this does not discount the possibility that effects could arise
when wild type Tfeb alleles are absent (Steingrimsson et al., 2002). As of yet, no such
investigation has been documented.
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Results
Tfeb was cloned into the pMX retroviral vector and site directed mutagenesis employed
to create the S401N point mutation. Each vector was overexpressed in 293T cells and
subsequent western blot analysis confirmed that Tfeb-S401N protein was stable and identical
sizes between wild type and mutant suggests that phosphorylation forms between the two
proteins are consistent (Fig A.4). Next, both pMX-Tfeb-WT and pMX-Tfeb-S401N TFEB were
overexpressed in expanded wild type BMMs. Despite varying densities of seeded BMMs,
exposure to RANKL enabled osteoclastogenesis in every condition, and no differences were seen
in OC formation between vector controls and either version of Tfeb by TRAP staining (Fig A.5).
Due to the presence of endogenous Tfeb in the BMMs potentially obscuring our results,
we obtained floxed Tfeb mice from the laboratory of Babak Razani, Ph.D., at Washington
University in St. Louis. We were provided bone marrow from floxed controls and animals
bearing the floxed plus LysM-cre alleles, Tfebfl/fl and Tfebfl/fl;LysMcre, respectively. Using
BMMs harvested from these animals, we repeated the infection protocol of pMX-Tfeb-WT and
pMX-Tfeb-S401N and found no effect of the mutation on OC formation or function as assayed
by TRAP stain, actin rings, and bone resorption pit assay (Fig A.6). Unexpectedly,
overexpression of both wild type and S401N Tfeb in BMMs resulted in decreased
osteoclastogenesis compared to empty vector controls. Furthermore, OC formation and function
by actin ring and resorption pit staining were comparable between WT and S401N-infected cells
on both wild type and Tfebfl/fl;LysMcre BMM backgrounds (Fig. A.6). However, qPCR of these
BMMs revealed a residual 10% of Tfeb expression. Knockdown to 0.5% was achieved by
adding additional cre to Tfebfl/fl;LysMcre BMMs in vitro. Here, resorption was slightly altered
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but osteoclastogenesis left intact, phenocopying to a small degree the changes observed when
Karsenty’s group used Cathepsin K-cre (Fig. A.6). (Destaing et al., 2003)
To further probe the effect of mutant Tfeb on the OC, we assayed the expression of
common Tfeb targets by quantitative real time PCR: p62 and ATP6v1h. No change in p62 or
ATP6v1h expression was seen at basal levels in Tfebfl/fl or Tfebfl/fl;LysMcre BMMs or OCs, or
when levels were induced following cell starvation of 3 hrs with lowered percent FBS (2%
compared to normal 10% in media) (Fig A.7). Here, as p62 and ATP6v1h levels rose in both
cell types to a similar extent we wondered whether the residual 10% of Tfeb expression in the
Tfebfl/fl;LysMcre samples was sufficient to create an effect. Further study was planned to
generate animals harboring two LysM-cre alleles, to mitigate this possibility and further
elucidate the contribution of Tfeb-S401N in the OC lineage when it is the only form of Tfeb
present in a mouse or cultured cell. A knock-in mouse model was also considered.
Concurrent with our laboratory studies, the mother of the deceased OC-poor OPT patient
gave birth to another son that was also affected with this condition, presenting with widened
metaphyses and epiphyseal plates, as well as hypocalcemia and seizures at two weeks of age.
His blood was sequenced for Tfeb, and it was found that he carried two wild type copies of the
gene, thus, eliminating Tfeb as a disease-causing candidate. Tfeb studies in the laboratory were
discontinued.
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Discussion
The genetic etiology of this particular case of OC-poor osteopetrosis remains unclear, and
further whole genome sequencing of the newborn affected child, parents, and unaffected sister
will be highly informative. Here, we expect to uncover additional candidate genes that
contribute to OC formation and thus, increase our general understanding of the differentiation of
this important cell type. Until this becomes an option, however, we have comfort in knowing
that the second affected child received a bone marrow transplant to allow OCs to form and
function in this individual.
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Figures and tables

Figure A.1: Patient of consanguineous parents exhibits clinical signs of OPT
Family pedigree in which the four pregnancies from first cousins resulted in two hydatidiform
molar (HM) pregnancies, a healthy girl, and boy with OC-poor OPT. B. Tibial bone core biopsy
reveals disorganized trabeculae with minimal bone matrix (grey). Cartilage stains purple and
cortex is thin (*). C. Radiographic imagine of patient’s spine, upper and lower extremities,
hand, and skull in which abnormally modeled metaphyses, as well as wide dense ribs, phalanges,
and skill base. Figures modified from Gary Gottesman, M.D.
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Figure A.2: CD14+ cells from patient carrying homozygous S400N Tfeb mutation do not
differentiate into mature OCs with actin rings compared to healthy family members and
unrelated controls
A-B). In vitro differentiation of CD14+ peripheral blood monocytes revealed patient has
diminished TRAP+ OC numbers compared to unaffected family members and unrelated controls
(quantified in B), with key to the bottom right, mean ± SD is representative of two experiments,
**p<0.01, ***p<0.001, scale bars = 1 mm. C) When grown on bone, the patient’s cells fail to
form actin rings, as shown by FITC-phalloidin. D). Patient cells express RANK, as determined
with primary OC cell lysates immunoblotted for RANK, and quantified by normalization to
father in red. Figures modified from Gary Gottesman, M.D.
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Figure A.3: Schematic representation of Tfeb
A. Amino acids lengths are shown and OC-poor OPT patient mutation location is identified. B.
Depiction of Tfeb’s role in autophagy, lysosome biogenesis, and exocytosis from (Settembre et
al., 2013)
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Figure A.4: Overexpression of S400N in 292T cells does not affect protein stability or
nuclear localization
A). Western blots against Tfeb in whole cell lysates (A), or nuclear and cytoplasmic extracts
(B), show no differences between WT and mutant forms of the protein.
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Figure A.5: In vitro addition of cre impacts bone resorption to a small degree while not
altering osteoclastogenesis
Cre was added retrovirally in culture. TRAP at 2X, resorption pits at 20X.
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Figure A.6: Overexpression of Tfeb S400N does not alter osteoclastogenesis on WT or cKO
backgrounds
Tfebfl/fl and Tfebfl/fl;LysMcre BMMs were retrovirally infected with constructs and treated with
15 ng/ml RANKL for 5 days. TRAP stained wells are shown at 2X, actin rings and resorption
pits at 20X.
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Figure A.7: Tfeb targets are altered with gene knockdown and induction with starvation
A). Tfeb expression is knocked down in cKO BMMs and OCs. B). p62 and ATP6v1h levels are
induced when cells are starved in 2% serum, however no differences are seen between controls
and cKO cells.
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Appendix B –
Osteomyelitis
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Abstract
Osteomyelitis (OM) is a severe bacterial infection of the bone associated with an
inflammatory reaction and disruption of skeletal integrity in which Staphylococcus aureus (S.
aureus) is the primary causative agent. Although S. aureus is considered to be an extracellular
pathogen, recent evidence indicates it can persist intracellularly in many cell types, including
osteoblasts (OB). Infected OBs produce RANKL and recruit osteoclasts (OCs) to the site of bone
infection, but the role of OCs in OM, and in particular their ability to become infected, is not
well understood. We hypothesized that S. aureus could infect OCs to contribute to OM
pathogenesis. While previous work in the laboratory utilized in vitro assay of S. aureus infection
of OCs, confirmation of the accuracy of this model between different bacterial and murine cells
was lacking. Work was done to confirm previous findings and take steps toward developing an
in vivo model of osteomyelitis.
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Introduction
Bacterial osteomyelitis is associated with inflammation and pain, and leads to bone loss
with increased susceptibility to atraumatic fractures. S. aureus is involved in over 60% of OM
cases, and treatment generally involves surgical debridement and intravenous antibiotics
(Calhoun et al., 2009; Lew and Waldvogel, 2004). Even so, recurrence is common, suggesting
that the bacteria may evade antibiotic treatment or capture by the immune system, thereby
allowing reactivation of disease at a later date. Surprisingly, little is known about mechanisms of
OM etiopathology.
Much of the work in OM pathogenicity has made progress in elucidating bacterial
survival strategies. For example, characterization of the Sae bacterial locus in S. aureus revealed
that alpha-type phenol-soluble modulin toxins act osteolytically to promote infection of the bone,
and epithelial cell infection studies showed that S. aureus organization into small colony variants
increases intracellular survival. (Cassat et al., 2013; Tuchscherr et al., 2010). Interestingly,
cultured OBs are susceptible to S. aureus infection, whereby the bacteria can alter these
mammalian cells to promote bone resorption in two ways: triggering OB death, and inducing
osteoclastogenesis (Alexander et al., 2003; Ellington, 1999; Hudson et al., 1995). In the latter, S.
aureus-infected OBs increase expression of proinflammatory cytokines that activate RANKL to
promote OC formation (Claro et al., 2013; Marriott et al., 2010; Somayaji et al., 2008). While
the recruitment and activation of OCs clearly contributes the osteolytic lesions found in OM, we
theorized there might be additional interactions between bacteria and the OC that hadn’t yet been
probed.
Previous work in our laboratory has used confocal imaging of decalcified calvaria
sections from TRAP-Td-Tomato reporter mice injected with GFP-labeled S. aureus over the
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periosteum to show that S. aureus is present within OCs following infection, in vivo. We have
performed an in vitro infection protocol to assay the ability of S. aureus to reside in
differentiating OCs. Primary expanded bone marrow macrophages (BMMs), cultured +/RANKL, are infected with S. aureus for 30 min, extracellular bacteria killed with 1 hr
gentamicin treatment, and cells cultured 16.5 hrs more prior to lysis; intracellular S. aureus
growth is assessed by colony forming assay, comparing numbers immediately following
gentamicin treatment with endpoint. We found that while BMMs cultured in M-CSF alone
reduce S. aureus, the same cells stimulated with M-CSF + RANKL experience increases of ~50fold (2 d RANKL) to ~500-fold (3 d RANKL) in intracellular bacteria. Further supporting the
requirement for OC lineage differentiation, intracellular S. aureus levels are diminished to BMM
levels in RANKL-treated cells lacking NFATc1 or NIK, which fail to form OC. To determine
whether increased bacterial recovery in mature OCs represents intracellular S. aureus
proliferation, we used a microscopy approach and observe replicating bacteria in infected OCs in
vitro by transmission EM (Krauss & Roper, et al., manuscript in preparation).
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Results
To probe the effect of S. aureus infection on the OC in vitro, our laboratory employs a
proliferation assay in which bacteria are incubated with BMM, pre-OC, or OC cells for 30 min at
a multiplicity of infection (MOI) of 1 or 10. Subsequently, gentamicin is added for 1 hour to kill
extracellular bacteria, and cells are lysed. Bacteria residing in the mammalian cells are
enumerated by plating on agar and growing colonies overnight. Wells not lysed are allowed to
grow for another 16.5 hrs prior to lysis and colony enumeration (18 hrs post-infection) (Fig. B.1
A). Here, in comparing the bacterial burden between 1.5 and 18 hr timepoints we find that while
BMMs are effective in killing bacteria, S. aureus replicates in day 2 pre-OCs and to an even
greater extent in day 3 mature OCs (Fig B.1 B). This same trend is seen regardless of murine
strain of BMMs or genetic modification of USA300 MRSA used in the laboratory (Fig B.2).
Because other groups using a similar gentamicin protection assay maintain the drug in the
cell culture media throughout the duration of the experiment to prevent escape of internalized
bacteria, we sought to attempt this alteration of the protocol (Elsinghorst, 1994). We repeated
the assay with two conditions: pulse treatment of gentamicin at 300µg/ml for 1 hour, or
continuous gentamicin at 30µg/ml for the duration of the assay. We find that continuous
presence of gentamicin abolishes our phenotype of S. aureus growth from 1.5 to 18 hrs (Fig B.3).
Importantly, cell culture media plated in each condition yielded no bacterial colonies, indicating
that with or without gentamicin presence in the media, no extracellular S. aureus replication is
occurring. As probed media only tested for free-floating S. aureus, this brought up the question
of whether once-internalized bacteria are replicating on the surface of the OC cells, and
prompted us to test whether additional washes of the culture wells would change our results. No
differences were detected between bacterial yields at 18 hrs with or without washing, suggesting
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all bacteria are truly internalized (Fig B.4). We conclude that the differences seen between pulse
vs. continual gentamicin treatment is due to the drug also being internalized by mammalian cells,
as has been reported by other groups (Kim et al., 2019). Here, our one-hour pulse gentamicin
treatment is sufficient to eliminate extracellular bacteria, and removing it from the media is
necessary to avoid its dual killing of intracellular bacteria.
To further support our theory that the OC provides a niche for S. aureus to persist and
replicate, we turned to confocal microscopy to demonstrate S. aureus internalization. To do this
we infected TRAP-TdTomato pre-OCs with a GFP-labeled USA300 MRSA strain, fixed cultures
in 4% paraformaldehyde, and mounted coverslips with a Dapi nuclear stain. Z-stack images
taken on Leica TCS SPE confocal system, and z-plane images confirm that green bacteria are
within the same plane as red OCs (Fig B.5), supporting internalization of S. aureus. Seeking
another method to further demonstrate the intracellularity of S. aureus, we fixed cultures of preOCs infected with GFP-USA300 with 70% ethanol, and performed flow cytometry. Gating
specimens by size and Hoechst staining revealed almost 25% of the population was
multinucleated (Fig B.6 A). Further, we detect a higher proportion of GFP-positive bacteriacontaining cells in infected samples, confirming for the first time by cytometry that S. aureus
resides directly within pre-OCs in vitro (Fig B.6 B).
As a goal of our laboratory is to develop an in vivo model of OM, we began developing
an infection model of the calvaria, a procedure previously done in our laboratory for imaging of
infected OCs in vivo. We anticipated that by inducing osteoclastogenesis at the calvaria with
RANKL injection we would create more opportunities for S. aureus to preferentially invade OCs
and replicate. We injected mice over the calvaria for 4 consecutive days prior to injecting
1.0x107 S. aureus cells at the same site. Calvaria were harvested 48 hrs later and crushed via
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bullet blending. Minced contents were plated on agar and colonies observed the next day. We
find that the RANKL-treated calvaria yield more bacterial colonies that PBS-treated calvaria,
suggesting the more abundant the OCs, the more likely S. aureus is to seed and replicate at that
site (Fig B.7 A-B). To further probe whether the presence of OC at the calvaria alters infection
by S. aureus, we repeated this model on animals lacking Nfatc1, the master transcriptional
regulator of OCs. Surprisingly, no differences were observed in bacterial burden between
control and Nfatc1 knockout calvariae (Fig. B.8). This may be due to a preference for bacteria to
form an abscess on the skin at the infection site rather than infiltration into the calvaria itself.
Many, but not all, animals had identifiable bacteria in the skin over the periosteum, likely
masking any trends that would have been seen in the bone had bacteria colonized there instead.
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Discussion
As our laboratory seeks to understand the etiopathology of OM in the OC, our primary
objective was to establish a solid in vitro model. Here, work done to verify that multiple strains
of S. aureus replicate in pre-OCs of different animal backgrounds brings confidence to the
precision of our assay. Furthermore, confirmation that bacteria are truly residing intracellularly
in our assay as well as demonstration of co-localization of S. aureus in OC cells by confocal
microscopy and flow cytometry supports our hypothesis that the OC serves as a replicative niche
for S. aureus during OM. Steps were also taken to begin developing an in vivo model of OM at
the calvaria. While data are unreliable due to high variability in the amount of bacteria that
seeded to the calvaria, the groundwork has been set for this work to continue. Currently, our
laboratory is building on these in vitro and in vivo results to better demonstrate S. aureus
intracellularity by microscopy and flow cytometry, as well as develop mouse models through
depositing bacteria directly into the tibia as well as tail vein.
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Figures and tables
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Figure B.1: In vitro infection protocol consistently captures S. aureus proliferation in
maturing OCs
A). Bone marrow macrophages and differentiating OCs are infected with S. aureus for 30 min
and extracellular bacteria killed by 1 h gentamicin treatment. Cells are lysed at 1.5 and 18 hrs
post-infection, and colony formation enumerated to quantify S. aureus growth or killing in this
16.5 hr period. B). S. aureus growth within 16.5 hrs is observed in cells treated with at 2-3 days
of RANKL exposure, while S. aureus is killed in BMMs cultures. Figure modified from work of
Emily Goering and Jennifer Krauss.

107

10000000
1000000

CFU

100000
10000
1.5 hrs

1000

18 hrs

100
10
1
WT cells + WT cells + TRAP cells TRAP cells
USA300
GFPsa
+ USA300 + GFPsa

Figure B.2: Different strains of S. aureus are capable of growth in OCs derived from mice
of different backgrounds
D3 OCs were generated from B6 and Trap-TdTomato mice and infected with USA300 or
USA300-GFP S. aureus. Growth is seen in each condition.

108

A

B
70000
60000
50000

CFU

40000
1.5 hrs

30000

18 hrs

20000
10000
0
-10000

D2

D3

300 µg/ml pulse gent

D2

D3

30 µg/ml continuous gent

Figure B.3: S. aureus growth is lost when antibiotic is kept in culture media throughout
infection timecourse
A). 1.5 and 18 hr agar plates display extensive growth in 1 hr 300 µg/ml pulse gentamicin
treatment compared to little change when 30 µg/ml gentamicin is continuously in media
following infection. B). CFU counts from D2 and D3 plates with different treatments are
enumerated.
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Figure B.4: Washing OCs at 18 hrs has no effect on recovered S. aureus by CFU assay
D3 OCs were infected with S. aureus and prior to OC lysis at 18 hrs, cells were or were not
washed with PBS to eliminate non-intra-cellular bacteria. Identical growth is observed in each
condition.
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Figure B.5: GFP-labeled St. aureus found within OCs 18-hrs post infection
Z-stack confocal imaging was used to visualize D3 TRAP-TdTomato OCs infected with GFPlabeled S. aureus. Green bacteria lie within the same plane of red OCs and dapi-stained nuclei,
suggesting bacteria are persisting within mammalian cells.
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Figure B.6: S. aureus is detected by flow cytometry of D2 OCs
A). D2 OCs infected with GFP-labeled S. aureus were fixed with 70% ethanol and stained with
Hoescht. Live cells were selected and Hoescht was used to gate on multinucleated cells. B).
FITC green signal is detected to a greater extend in GFPstaph-infected OCs (blue) compared to
uninfected OC cells (red) in total, multinucleated, and mononucleated cell populations.
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Figure B.7: RANKL-treated calvaria yield more S. aureus than PBS-treated calvaria
A). Schematic of experiment whereby 2 mk/kg RANKL or PBS was injected subcutaneously
over the perisosteum of the calvaria prior to S. aureus. Bacteria were enumerated by CFU assay
48 hrs post infection. B). More S. aureus colonies are recovered from RANKL-treated calvaria
(bottom) compared to PBS controls (top).
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Figure B.8: Loss of Nfatc1 does not affect S. aureus infection of the calvaria
Nfatc1fl/fl (ctrl) and Nfatc1fl/fl; cre (KO) mice were treated with RANKL over the calvaria for 4
days prior to inoculation with S. aureus in the same location. Enumeration of bacterial residence
48 hrs post-infection reveals no difference between groups of animals.
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